



Islamic University – Gaza
College of science
Master Degree of
Biological Science/ Zoology

**Obestatin level and some biochemical parameters in
type 2 diabetic women attending Medical Relief Center
in Gaza Governorate**

**Submitted in Partial Fulfillment for the degree of Master
of Science in Biological Sciences- Zoology**

Prepared by:
Mona M. Hamam
B.Sc. Medical Technology

Supervisor:
Prof. Dr. Maged M. Yassin
Professor of Physiology
Faculty of Medicine
The Islamic university of Gaza

September, 2012

Dedication

To my parents who have always supporting me

To my husband Rashad who helped me to accomplish this thesis.

To my children, Renad and Kareem

To my brothers and sisters

To my university The Islamic university of Gaza which is continuously improving the research

To all of them I dedicate this work

Mona M. Hamam

Declaration

I certify that this submission is my own research and that, to the best of my knowledge and belief, it contains material neither previously published or written by another person nor material which to a substantial extent has been accepted for the award of any other degree of the university of other institute, except where due a acknowledgment has been made in the text.

Signature

Mona

Name

Mona M. Hamam

Date

September, 2012

Acknowledgment

I would like to express my deepest gratitude and appreciation to my supervisor

Prof. Dr Maged M. Yassin, Professor of Human Physiology, Faculty of Medicine,

The Islamic University of Gaza for his continuous support, encouragement and kind of supervision that leads to the emergence of this work in its current form.

I would like to thank The Islamic University of Gaza and the Faculty of Science for giving me the opportunity and knowledge to achieve this research.

All the staff members and colleagues of Medical Technology Master Program.

I would like to highly thank administration and laboratory staff of Medical Relief Center-Gaza, for their assistance in samples analysis, the director Mr. **Mohammad Abu Afash**.

I would like to thank Mr. Abdul Rahman Hamad for his help in statistical analysis.

My special thanks to Al Arabi lab for their kind help.

At the end, I am very grateful to those who participated and helped me to complete this study.

Obestatin level and some biochemical parameters in type 2 diabetic women attending Mediact Relief Center in Gaza

Abstract

Background: Obestatin is a novel 23-amino acid peptide derived from the mammalian prepro-ghrelin polypeptide. Recent studies demonstrated that obestatin is a metabolic hormone associated with type 2 diabetes. Therefore, assessment the status of obestatin and clarifying such association in diabetes could constitute a promising therapy of the disease.

Objective: To asses obestatin level and some biochemical parameters among type 2 diabetic women attending Mediact Relief Center in Gaza.

Materials and Methods: This case-control study comprised 64 type 2 diabetic women and 64 healthy non diabetic women. Questionnaire interview was applied. Serum obestatin was measured by ELISA. Serum glucose, cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), urea and creatinine were determined. Blood HbA1c was also measured. Data were computer analyzed using SPSS version 18.0.

Results: The mean ages of controls and cases were 52.7 ± 8.9 and 52.9 ± 8.3 years. Type 2 diabetes was found to be significantly associated with family history and diet. More than half of patients had diabetes since less than 5 years. The main self-reported complications among patients were neuropathy, retinopathy and cardiovascular disease. The longer the duration of diabetes, the higher the prevalence of self-reported complications. The mean level of serum obestatin was significantly lower in diabetic women compared to healthy non diabetic controls (3.4 ± 0.8 ng/ml vs. 4.1 ± 1.5 ng/ml, $P=0.023$). The mean HbA1c and glucose levels in cases were significantly higher than that in controls (6.4 ± 0.9 and 190.7 ± 86.7 vs 4.7 ± 0.6 and 101.6 ± 21.0) with $P=0.000$. The Pearson correlation test showed negative significant correlations between obestatin levels and HbA1c and glucose ($r=-0.320$, $P=0.009$ and $r=-0.469$, $P=0.000$ respectively). The average level of triglycerides was significantly increased in diabetic women (183.3 ± 80.0 mg/dl) compared to controls

(122.4±42.9 mg/dl) with P=0.000. On the other hand, HDL-C was significantly lower in cases (40.7±11.2vs. 47.2±12.0mg/dl, % difference=14.8 and t=2.228, P=0.030). The Pearson correlation test showed negative significant correlations between obestatin levels and triglycerides levels (r=-0.275, P=0.026).

Conclusions: Serum obestatin was significantly lower in diabetic women compared to healthy non diabetic women. There were negative significant associations between obestatin levels with HbA1c, glucose and triglycerides levels.

Keywords: Obestatin, diabetes, HbA1c, glucose, lipid profile, Gaza.

مستوى الأوبستاتين وبعض المعايير الكيميائية لدى مرضى السكري من النوع الثاني من

الاناث اللواتي يرتدن مركز الاغاثة الطبية في غزة

المقدمة: اكتشف هرمون الأوبستاتين حديثا وهو يتكون من 23 حمض اميني مشتق من عديد الببتيد بدائي الجريلين في الثدييات. وقد اظهرت الدراسات الحديثة ان الأوبستاتين هرمون متعلق بالأبيض ويرتبط بمرض السكري من النوع الثاني ولذلك فان تقييم حالة الأوبستاتين وتوضيح هذا الارتباط في مرض السكري ممكن ان يشكل علاج واعد لهذا المرض.

الهدف: تهدف الدراسة الى قياس مستوى هرمون الأوبستاتين وبعض المعايير البيوكيميائية في مرضى السكري من النوع الثاني من الاناث اللواتي يرتدن مركز الاغاثة الطبية في غزة.

الطرق والادوات: منيح الدراسة (مجموعة مرضية-مجموعة ضابطة)، المجموعة المرضية تحتوي على 64 امرأة مصابة بالنوع الثاني من داء السكري والمجموعة الضابطة تحتوي على 64 امرأة غير مصابة بداء السكري. تم الحصول على البيانات المستخدمة في الدراسة من خلال المقابلة المباشرة مع المرضى. تم قياس مستوى كل من هرمون الأوبستاتين، السكر، الكوليسترول، الدهون الثلاثية، البروتين الدهني عالي الكثافة، البروتين الدهني منخفض الكثافة، البوليبيد و الكرياتينين وايضا تم قياس نسبة ارتباط السكر بالهيموجلوبين في الدم. تم تحليل البيانات والنتائج التي تم الحصول عليها باستخدام البرنامج الاحصائي المحوسب spss 18.0.

النتائج: كان متوسط العمر للمجموعة الضابطة هو 52.7 ± 8.9 سنة ومتوسط العمر للمجموعة المرضية هو 52.9 ± 8.3 سنة. اوضحت النتائج ان مرض السكري يرتبط بالتاريخ العائلي والتغذية وان اكثر من نصف مرضى السكري يعانون من السكري منذ خمس سنوات او اقل. كما ان المضاعفات الرئيسية التي سجلت على لسان المرضى اوضحت وجود اعتلال الاعصاب واعتلال الشبكية وامراض القلب والاعوية الدموية وانه كلما زادت مدة الاصابة بالسكري كلما زادت نسبة المضاعفات بين المرضى. وقد اظهرت النتائج أن متوسط مستوى هرمون الأوبستاتين كان أقل في المجموعة المرضية مقارنة بالمجموعة الضابطة وقد كانت النتائج ذات دلالة إحصائية. كانت نتيجة متوسط كل من الجلوكوز ونسبة ارتباط السكر بالدم أعلى بدلالة احصائية في المجموعة المرضية منها في المجموعة الضابطة. وقد اظهرت النتائج وجود علاقة عكسية بين مستوى هرمون الأوبستاتين والجلوكوز ونسبة ارتباط السكر بالهيموجلوبين (مخزون السكر). كانت نتيجة متوسط مستوى الدهون الثلاثية أعلى بدلالة احصائية في المجموعة المرضية منها في المجموعة الضابطة. اما مستوى البروتين الدهني عالي الكثافة فقد كان اقل بدلالة احصائية في المجموعة المرضية منها في المجموعة الضابطة. و اظهرت النتائج وجود علاقة عكسية ذات دلالة احصائية بين الدهون الثلاثية و مستوى هرمون الأوبستاتين حيث كلما زادت الدهون الثلاثية كلما قل مستوى هرمون الأوبستاتين.

الاستنتاجات: تبين ان مستوى هرمون الأوبستاتين أقل بدلالة احصائية في النساء المصابات بداء السكري من النوع الثاني مقارنة مع النساء الغير مصابات. كما انه توجد علاقة عكسية ذات دلالة احصائية بين هرمون الأوبستاتين و الجلوكوز ،نسبة ارتباط السكر بالهيموجلوبين والدهون الثلاثية.

الكلمات المفتاحية: الأوبستاتين، الجلوكوز، نسبة ارتباط السكر بالدم ، الدهون، السكري، غزة.

Table of Contents

Contents	Page
Dedication	i
Declaration	ii
Acknowledgement	iii
Abstract (English)	v
Abstract (Arabic)	vii
Table of Contents	viii
List of tables	xiii
List of figures	xiv
Abbreviations	xv
Chapter 1: Introduction	1
1.1 Overview	1
1.2 General objective	3
1.3 Specific objectives	3
1.4 Significance	3
Chapter 2: Literature Review	4
2.1 Definition of diabetes mellitus	4
2.2 Types of diabetes	4
2.2.1 Type 1 diabetes	4

2.2.2 Type 2 diabetes	4
2.2.3 Gestational diabetes	5
2.3 Prevalence and mortality rate of diabetes mellitus	5
2.4 Type 2 diabetes	6
2.4.1 Metabolism in type 2 diabetes	6
2.4.2 Complications of type 2 diabetes mellitus	7
2.4.2.1 Retinopathy	8
2.4.2.2 Diabetic neuropathy	8
2.4.2.3 Cardiovascular disease	8
2.5 Obestatin	9
2.5.1 Definition and site of secretion	9
2.5.2 Biosynthesis	9
2.5.3 Obestatin in plasma and its degradation	10
2.5.4 Biological effects of obestatin	11
2.5.4.1 Appetite and body weight	11
2.5.4.2 metabolism	12
2.5.4.3 Growth hormone secretion	12
2.5.4.4 Reproduction	13
2.5.4.5 Gastrointestinal function	13
2.5.4.6 Cellular proliferation	13
2.5.4.7 Bone physiology	13
2.5.4.8 Other effects	14

2.6 Related studies	15
Chapter 3: Materials and Methods	18
3.1 Study design	18
3.2 Study population	18
3.3 Sampling and sample size	18
3.4 Exclusion criteria	18
3.5 Ethical Considerations	19
3.6 Data collection	19
3.6.1 Questionnaire interview	19
3.6.2 Body mass index	19
3.6.3 Specimen collection and biochemical analysis	20
3.7 Biochemical analysis	20
3.7.1 Determination of serum obestatin	20
3.7.2 Determination of glycohemoglobin (HbA1c) in Whole blood	24
3.7.3 Determination of serum glucose	26
3.7.4 Determination of serum cholesterol	27
3.7.5 Determination of serum triglycerides	29
3.7.6 Determination of serum high density lipoprotein (HDL-C)	30
3.7.7 Determination of low density lipoprotein -cholesterol (LDL- C)	32
3.7.8 Determination of serum urea	32
3.7.9 Determination of serum creatinine	34
3.8 Statistical analysis	36

Chapter 4: Results	37
4.1 Sociodemographic data of the study population	37
4.2 Diet and drug therapy among the study population	38
4.3 Distribution of diabetic patients by the duration of the disease	39
4.4 Self-reported complications of the study population	40
4.5 Self-reported complications among patients in relation to the duration of diabetes	40
4.6 Anthropometric measurements of the study population	41
4.7 Serum obestatin levels of the study population	42
4.8 HbA1c and glucose of the study population	42
4.9 Serum lipid profile of the study population	43
4.10 Serum urea and creatinine of the study population	44
4.11 Obestatin levels in relation to BMI of the study population	45
4.12 Obestatin levels in relation to HbA1c and glucose of the study population	45
4.13 Obestatin levels in relation to lipid profile of the study population	47
4.14 Obestatin levels in relation to urea and creatinine of the study population	48
Chapter 5: Discussion	49
5.1 Family history and diet among the study population	49
5.2 Diabetes duration and self-reported complications	50

5.3 Diabetes and body mass index	50
5.4 Serum obestatin of the study population	51
5.5 HbA1c and glucose of the study population	51
5.6 Lipid profile of the Study population	52
5.7 Urea and creatinine concentrations of the study population	53
Chapter 6: Conclusion and Recommendations	54
6.1 Conclusion	54
6.2 Recommendations	55
Annex 1	56
References	58

List of tables	Page
Table 4.1 Sociodemographic data of the study population	38
Table 4.2 Diet and drug therapy among the study population	39
Table 4.3 Distribution of diabetic patients (n=64) by the duration of the disease	39
Table 4.4 The main self-reported complications among the study population (n=128)	40
Table 4.5 Self-reported complications among patients in relation to the duration of diabetes	41
Table 4.6 Anthropometric measurements of the study population	42
Table 4.7 Serum obestatin levels of the study population	42
Table 4.8 HbA1c and glucose of the Study population	43
Table 4.9 lipid profile of the Study population	44
Table 4.10 Serum urea and creatinine concentration of diabetic patients and controls	45
Table 4.11 obestatin levels in relation to BMI of the study population	45
Table 4.12 Obestatin levels in relation to HbA1c and glucose of the study population	46
Table 4.13 Obestatin levels in relation to lipid profile of the study population	47
Table 4.14 Obestatin levels in relation to Urea and creatinine of the study population	48

List of figures	Page
Figure 2.1 A diagram illustrating sequential steps of the production of three ghrelin gene products and their relationship with GOAT	10
Figure 4.1 Correlation between obestatin hormone level with HbA1c of the study population.	46
Figure 4.2 Correlation between obestatin hormone level with fasting blood glucose of the study population.	46
Figure 4.3 Correlation between obestatin hormone level with triglyceride level of the study population.	47

Abbreviations

Adenosine diphosphate	ADP
Adenosine triphosphate	ATP
Adenylyl cyclase	AC
Advanced glycosylated end-products	AGEs
Body Mass Index	BMI
Cardiovascular disease	CVD
Center for Disease Control and prevention	CDC
Cholesterol esterase	CHE
Cholesterol oxidase	CHOD
Cyclic Adenosine mono-phosphate	cAMP
Deoxyribonucleic acid	DNA
Diabetes mellitus	DM
Diastolic blood pressure	DBP
Enzyme immunoassay	EIA
Enzyme linked immunosorbant assay	ELISA
Ethylenediamine tetraacetic acid	EDTA
Extracellular signal-regulated kinase	ERK
Fasting plasma glucose	FPG
Gestational diabetes	GD
G protein-coupled receptor 39	GPR39
Ghrelin-O-acyltransferase	GOAT
Glucagon-like peptide-1	GLP-1
Glucagon-like peptide-1 receptor	GLP-1R
Glucose-dependent insulintropic peptide	GIP
Glycerol kinase	GK
Glycerol phosphate oxidase	GPO
Growth hormone	GH
Growth hormone secretagogue receptor type 1a	GHS-R1a
Hemoglobin A1c	HbA1c
High density lipoprotein cholesterol	HDL-C
Horse radish peroxidase	HRP

Immunoglobulin G	IgG
Impaired glucose regulation	IGR
Impaired glucose tolerance	IGT
Lipoproteinlipase	LPL
Low density lipoprotein cholesterol	LDL-C
MAP kinase kinase	MEK
Messenger ribonucleic acid	mRNA
Mitogen activated protein kinase	MAPK
Nicotinamide adenine dinucleotide	NAD+
Normal glucose tolerance	NGT
Palestinian clinical laboratory tests guide	PCLTG
Peroxidase	POD
Protein kinase A	PKA
Statistical Package of Social Sciences	SPSS
Streptavidin	SA
Systolic blood pressure	SBP
Tetramethylbenzidine	TMB
The homeostasis model assessment of insulin resistance	HOMA-IR
Triglyceride	TG
Type 2 diabetes mellitus	T2DM
United Kingdom	UK
United States	US
Very low density lipoprotein cholesterol	VLDL-C
Waist-to-hip ratio	WHR
World Health Organization	WHO

Chapter 1

Introduction

1.1 Overview

Diabetes mellitus represents a group of diseases of heterogeneous etiology, characterized by chronic hyperglycemia and other metabolic abnormalities, which are due to deficiency of insulin action, insulin secretion or both. Two major forms of diabetes were identified; type 1 and type 2. Lack of or severe reduction in insulin secretion due to autoimmune or viral destructions of β cells is responsible for type 1 diabetes, which accounts for 5-10% of diabetic patients. The more prevalent form, type 2 diabetes, accounts for more than 90% of cases (Olefsky, 2001). Type 2 diabetes usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. As the need for insulin rises, the pancreas gradually loses its ability to produce it (Cohen, 2006).

Lack of insulin action and/or secretion in type 2 diabetes induces hepatic glucose output by inhibiting glycogen synthesis and stimulating glycogenolysis and gluconeogenesis then increased rates of hepatic glucose production result in the development of overt hyperglycemia, especially fasting hyperglycemia (DeFronzo and Simonson, 1992 and Michael et al., 2000). In such conditions, lipolysis in adipose tissue is promoted leading to elevated circulating levels of free fatty acids. In addition, excess fatty acids in serum of diabetics are converted into phospholipids and cholesterol in liver. These two substances along with excess triglycerides formed at the same time in liver may be discharged into blood in the form of lipoproteins (Jaworski et al., 2007). In addition, disturbance in serum urea and creatinine was also reported in type 2 diabetes (Sharma et al., 2011 and Yassin et al., 2011).

Obestatin is one of the three ghrelin gene products. It is a novel 23-amino acid peptide derived from the mammalian prepro-ghrelin polypeptide (Zhang

et al., 2005). The expression of obestatin was reported in cells of the gastric mucosa, myenteric plexus and perinatal pancreas and in Leydig cells of the testis (Zhang et al., 2005; Chanoine et al., 2006 and Dun et al., 2006). Obestatin binds to an orphan G protein-coupled receptor, termed GPR39, to inhibit food intake (Zhang et al., 2005). On the other side, obestatin manifested various biological functions, such as improving memory performance, causing anxiolytic effects (Carlini et al., 2007), inhibiting thirst in rats (Samson et al., 2007), activating cortical neurons (Dun et al., 2006), stimulating proliferation of retinal pigment epithelial cells in vitro (Camiña et al., 2007), and profoundly influencing sleep (Szentirmai and Krueger, 2006b and Szentirmai et al., 2009).

There is great controversy about the effects of obestatin on food intake with some studies suggesting that it may inhibit food intake and suppress body weight under basal and ghrelin-stimulated conditions (Bresciani et al., 2006; Zizzari et al., 2007 and Hassouna et al., 2010) and others suggesting no effect (Seoane et al., 2006 and Gourcerol et al., 2007). In addition, articles linked obestatin and diabetes mellitus were very few and recent. Obestatin status in type 2 human diabetes remains controversial. One study showed decreasing concentration of obestatin with type 2 diabetes and impaired glucose regulation and insulin resistance (Qi et al., 2007). In another study, St-Pierre et al., (2010) showed that normal and diabetic subjects displayed similar levels of circulating obestatin in fasting condition. However, patients with type 2 diabetes looked refractory to the inhibitory effect of meal on obestatin secretion. Regarding lipid metabolism, it was reported that obestatin treatment led to decrease in plasma triglycerides (Nagaraj et al., 2008 and 2009 and Agnew et al., 2011).

Although the prevalence of diabetes in Gaza Strip is alarming, the available studies are limited and biochemical data are only restricted to traditional tests when the patient visits the clinic. However, a recent study investigated the status of leptin hormone in type 2 diabetic patients in Gaza Strip (Altawil, 2009). No previous study was conducted on the novel hormone obestatin in type 2 diabetes in Gaza Strip or even in the Arab World. Therefore, this study

will be the first study to assess obestatin status in type 2 diabetic females in Gaza Governorate, Gaza Strip.

1.2 General objective

The general objective of the present study is to assess obestatin level and some biochemical parameters in type 2 diabetic women attending Medical Relief Center in Gaza.

1.3 The specific objectives were:

1. To investigate obestatin level in type 2 diabetic women and compared them with healthy controls.
2. To determine HbA1c in blood and serum glucose, lipid profile including cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), urea and creatinine in diabetic patients and controls.
3. To study sociodemographic and clinical data in type 2 diabetic patients.
4. To verify the relationships of obestatin with the previous parameters.

1.4 Significance

1. Diabetes mellitus is prevalent globally as well as in the Gaza Strip, and leads to high rates of morbidity and mortality.
2. Globally, there are few studies linked obestatin with type 2 diabetes. Of course, this will be the first study to describe obestatin levels in type 2 diabetic patients in Gaza Strip or even in the Arab world.
3. Understanding the role of obestatin in diabetes mellitus may make it a promising target for the developing of new drugs for the treatment of the disease.

Chapter 2

Literature Review

2.1 Definition of diabetes mellitus

It is a metabolic disorder characterized by chronic hyperglycemia due to disturbances of carbohydrate, fat and protein metabolism that are associated with absolute or relative deficiencies in insulin secretion, insulin action or both. Diabetes poses a major and growing health and socio-economic burden on society that affects over 177 million people worldwide and this figure is likely to be more than double by the year 2030 (WHO, 2003).

2.2 Types of diabetes

The most common types of diabetes mellitus are:

2.2.1 Type 1 diabetes

Type 1 diabetes indicates the processes of beta-cell destruction that may ultimately lead to diabetes mellitus in which insulin is required for survival to prevent the development of ketoacidosis, coma and death. It is characterized by the presence of islet cell or insulin antibodies which lead to beta cell destruction. Type 1 diabetes accounts for 5-10% of all diagnosed cases of diabetes (Olefsky, 2001). Despite 30 years of research, the cause of type-1 diabetes remains unknown (Wilkin, 2006).

2.2.2 Type 2 diabetes

Type 2 diabetes mellitus is a heterogeneous syndrome which accounts for about 90-95% of all diagnosed cases of diabetes. The causes of type 2 diabetes are multi-factorial and caused by a group of both genetic and environmental elements that affect beta-cell function and tissue (muscle, liver, adipose tissue, pancreas) insulin sensitivity (Scheen, 2003). Type 2 diabetes develops in individuals who fail to compensate for insulin resistance by

increasing pancreatic insulin secretion. This insulin deficiency results from pancreatic beta-cell dysfunction and death (Cnop, 2008).

2.2.3 Gestational diabetes

Gestational Diabetes (GD) is defined as any degree of glucose intolerance which begins or is first recognized during pregnancy. The risk for developing type 2 diabetes within the first decade following pregnancy in GD cases ranges between 35% and 60% (Wroblewska-Seniuk et al., 2009). Similarly, children of women with GD are known to be at risk for obesity and diabetes mellitus in their later life (Bánhidý et al., 2011).

2.3 Prevalence and mortality rate of diabetes mellitus in Palestine

The prevalence of diabetes mellitus in Palestine was examined in a study conducted in 2000 in cooperation with Al-Quds University and Ministry of Health. The results indicated that the prevalence was about 9% (Ministry of Health, 2002). It is around the reported prevalence rate in Egypt and Tunisia (9%) and less than in Saudi Arabia (12%) and Oman (13%). However, in Palestine, there is under-diagnosis and under-reporting of the disease. This is due to lack of proper hospital and clinic recording system (Ministry of Health, 2005). The mortality rate of diabetes mellitus among Palestinians constituted 5.9 per 100,000 population in the year 2009 (Ministry of Health 2009), and this figure raised to 8.5 per 100,000 population in the year 2010 (Ministry of Health 2010).

2.4 Type 2 diabetes

2.4.1 Metabolism in type 2 diabetes

Circulating glucose is derived from 1) intestinal absorption during the fed state in which the rates of gastric emptying determine how quickly glucose appears in the circulation during the fed state, and from 2) hepatic processes including glycogenolysis and gluconeogenesis. Renal gluconeogenesis contributes substantially to the systemic glucose pool only during periods of extreme starvation. Although most tissues have the ability to hydrolyze glycogen, only the liver and kidneys contain glucose-6-phosphatase, the enzyme necessary for the release of glucose into the circulation.

The rate of glucose entering the circulation balanced by the rate of glucose removal from the circulation. The glucoregulatory hormones of the body are designed to maintain circulating glucose concentrations in a relatively narrow range. Glucoregulatory hormones include insulin, glucagon, amylin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulintropic peptide (GIP), epinephrine, cortisol, and growth hormone. Of these, insulin and amylin are derived from the β -cells, glucagon from the α -cells of the pancreas, and GLP-1 and GIP from the L-cells of the intestine.

In the bi-hormonal model of glucose homeostasis, insulin is the key regulatory hormone of glucose disappearance, and glucagon is a major regulator of glucose appearance. After reaching a post-meal peak, blood glucose slowly decreases during the next several hours, eventually returning to fasting levels. In the immediate post-feeding state, glucose removal into skeletal muscle and adipose tissue is driven mainly by insulin. At the same time, endogenous glucose production is suppressed by 1) the direct action of insulin on the liver, and 2) the paracrine effect or direct communication within the pancreas between the α - and β -cells, which results in glucagon suppression (Wallum et al., 1992).

Type 2 diabetes is a disorder characterized by lack of insulin action and/or secretion that induces hepatic glucose output by inhibiting glycogen synthesis and stimulating glycogenolysis and gluconeogenesis then increased rates of

hepatic glucose production result in the development of overt hyperglycemia, especially fasting hyperglycemia (DeFronzo and Simonson, 1992 and Michael et al., 2000).

In such conditions, lipolysis in adipose tissue is promoted leading to elevated circulating levels of free fatty acids. Ketones are produced, and are found in large quantities in ketosis, the liver converts fat into fatty acids and ketone bodies which can be used by the body for energy (Botton and Green, 1999). In addition, excess fatty acids in serum of diabetics are converted into phospholipids and cholesterol in liver. These two substances along with excess triglycerides formed at the same time in liver may be discharged into blood in the form of lipoproteins (Jaworski et al., 2007). Several studies showed that cholesterol, triglycerides and LDL-C are elevated in diabetic patients (Barrett-Connor et al., 1982). In contrast, other studies documented that HDL-C was decreased (Yassin et al., 2011). In addition, disturbance in serum urea and creatinine was also reported in type 2 diabetes (Sharma et al., 2011).

2.4.2 Complications of type 2 diabetes mellitus

Complications of type 2 diabetes include acute and chronic complications. The acute complications comprise diabetic ketoacidosis, hyperosmolar hyperglycemic non ketotic coma, lactic acidosis and hypoglycemia (Bardin, C.W. 1994 and Harris et al., 1995). The chronic complications include cardiovascular disease, peripheral vascular disease, cerebrovascular disease, diabetic retinopathy and diabetic nephropathy (Savage, 1996; Dyck et al., 2002; Bate and Jerums, 2003; Susztak et al., 2003 and The National Eye Institute, 2006). Other complications include foot problems and leg amputations, skin disorders, decreased cognitive abilities and dementia, sexual dysfunction, pregnancy complications, some types of cancer, yeast infections, urinary tract infections, gingivitis, thrush, tuberculosis and other infections (Debra Manzella, 2008).

2.4.2.1 Retinopathy

The risk of developing diabetic retinopathy or other microvascular complications of diabetes depends on both the duration and the severity of hyperglycemia. Retinopathy may begin to develop as early as 7 years before the diagnosis of diabetes in patients with type 2 diabetes. Retinopathy involves changes in the retina. These changes happen because of damage or growth problems in the small blood vessels of the retina. Usually, changes in the retinal blood vessels don't appear before a person has reached puberty. One reason why diabetes needs to have regular yearly eye exams is because people with retinopathy may not have any problems seeing at first. But if the condition gets worse, they can become blind. A person with diabetes may be able to slow or reverse the damage caused by retinopathy by improving blood sugar control. If retinopathy becomes more advanced, laser treatment may be needed to help prevent vision loss (The National Eye Institute, 2006).

2.4.2.2 Diabetic neuropathy

Diabetic neuropathy can affect nerves in many different parts of the body. The most common early symptoms of the condition are numbness, tingling, or sharp pains in the feet or lower legs. An estimated 50% of those with diabetes have some form of neuropathy, but not all with neuropathy have symptoms. The highest rates of neuropathy are among people who have had the disease for at least 25 years. Diabetic neuropathy also appears to be more common in people who have had problems controlling their blood glucose levels, in those with high levels of blood fat and blood pressure, overweight people, and people over the age of 40 (Dyck et al., 2002). If it's not treated, nerve damage can cause a number of problems. For example, because of the numbness, people with nerve damage might not realize that they have a cut, and it could become seriously infected before they discover it (Debra Manzella, 2006).

2.4.2.3 Cardiovascular disease

Cardiovascular disease is the number one killer of people with type 2 diabetes, people with diabetes developing certain problems with the heart and blood vessels. Some of these problems are Heart attack, stroke and blockage

of blood vessels in the legs and feet, which can lead to foot ulcers, infections, and even loss of a toe, foot, or lower leg (Marshall, 2006). Myocardial ischemia due to coronary atherosclerosis commonly occurs without symptoms in patients with diabetes. As a result, multivessel atherosclerosis often is present before ischemic symptoms occur and before treatment is instituted. A delayed recognition of various forms of coronary heart disease undoubtedly worsens the prognosis for survival for many diabetic patients. One reason for the poor prognosis in patients with both diabetes and ischemic heart disease seems to be an enhanced myocardial dysfunction leading to accelerate heart failure. Several factors probably underlie diabetic cardiomyopathy: severe coronary atherosclerosis, prolonged hypertension, chronic hyperglycemia, microvascular disease, glycosylation of myocardial proteins, and autonomic neuropathy (Savage, 2005).

2.5 Obestatin

2.5.1 Definition and site of secretion

Obestatin is a novel 23-amino acid peptide derived from the mammalian prepro-ghrelin polypeptide, with molecular weight 2546.8 (Zhang et al., 2005). The expression of obestatin was reported in cells of the gastric mucosa, myenteric plexus and perinatal pancreas, mammary gland, breast milk, Leydig cells of the testis, spleen and in plasma and saliva (Zhang et al., 2005; Chanoine et al., 2006; Dun et al., 2006; Aydin et al., 2008; Grönberg et al., 2008 and Ozbay et al., 2008).

2.5.2 Biosynthesis

Obestatin is one of the three ghrelin gene products. The sequential steps of the production of three ghrelin genes products and their relationship with ghrelin O-acyltransferase (GOAT) is illustrated in Figure 2.1 (Chen et al., 2009). The described wild-type human ghrelin mRNA codes for a 117 amino acid long peptide, preproghrelin. Preproghrelin contains a 23 amino-acid signal peptide and a 94 amino-acid called pro-ghrelin (1–94). This includes the 28 amino acid mature ghrelin (1–28) and a 66 amino acid tail (29–94)

(Jeffery et al., 2005). Recent evidence suggests that the 66 amino acid tail of wild type proghrelin (29–94) can circulate as a full-length peptide (C ghrelin) or be processed to smaller peptides, mainly obestatin. There may be two types of C-ghrelin: one derived from the wild type proghrelin and one derived from the exon 3 (or exon 4)-deleted proghrelin (Soares and Leite-Moreira, 2008).




Figure 2.1. A diagram illustrating sequential steps of the production of three ghrelin genes products and their relationship with ghrelin O-acyltransferase, GOAT(Chen et al., 2009).

2.5.3 Obestatin in plasma and its degradation

Similar to ghrelin and growth hormone, obestatin is secreted in a pulsatile manner. Obestatin and ghrelin amounts in human plasma were found to be 6.9 ± 0.28 and 132.4 ± 13.1 fmol/ml, respectively with ratio of obestatin to ghrelin (%) 5.21 (Mondal et al. 2008). Plasma obestatin was below the detectable

value (less than 0.2 fmol) in rats. Differences in the metabolic degradation kinetics of human obestatin and mouse obestatin were found in plasma, liver and kidney, with half- lives ranging between 12.6 and 138.0 min (Vergote et al., 2008).

2.5.4 Biological effects of obestatin

It was originally projected that obestatin binds to an orphan G protein-coupled receptor, termed GPR39 (Zhang et al., 2005). High levels of GPR39 mRNA were found abundantly in the amygdala, the hippocampus, and the auditory cortex but not in the hypothalamus (Jackson et al., 2006). However, Lauwers et al., (2006) indicated that obestatin is not the endogenous cognate ligand for GPR39, whereas a more recent study demonstrated that obestatin was a metabolic hormone capable of binding to GPR39 and, in turn, of regulating the diverse biological functions of gastrointestinal and adipose tissues (Zhang et al., 2008). Furthermore, Granata et al. (2008) reported that obestatin promotes beta cell and human islet survival by binding to glucagon-likepeptide-1 receptor (GLP-1R), the receptor through which incretins act. Similarly, incretins also reduce gastrointestinal motility with a paracrine peripheral action and induce satiety and reduce food intake in the hindbrain specifically in the postrema and nucleus of the solitary tract (Yamamoto et al., 2003 and Holst, 2007). To date, the receptor for obestatin remains unknown and further studies are required to reveal the exact relationship between obestatin, GPR39 and GLP-1R.

2.5.4.1 Appetite and body weight

There is great controversy about the effects of obestatin on food intake with some studies suggesting that it may inhibit food intake and suppress body weight under basal and ghrelin-stimulated conditions (Zhang et al., 2005; Bresciani et al., 2006 and Zizzari et al. 2007), and others suggesting no effect (Seoane et al., 2006 and Gourcerol et al., 2007). Recent studies have partially clarified this issue. In one of these studies, intraperitoneal obestatin suppressed food intake and body weight gain in rodent in a U-shaped dose–response relationship. This relationship may explain the difficulties in

reproducing the effects of obestatin on feeding reported by some groups (Lagaud et al., 2007). In the other study, intracerebroventricular administration of obestatin inhibited water drinking in ad libitum-fed and -watered rats, and in food- and water-deprived animals (Samson et al., 2007). The effects on water drinking preceded and were more pronounced than any effect on food intake, and did not appear to be the result of altered locomotor/behavioral activity. Thus, it appears that obestatin possess biologic activity but that the effect on food intake may be secondary to an initial action in inhibiting thirst phenomenon referred to by some authors as dehydration anorexia (Samson et al., 2007).

2.5.4.2 Metabolism

Data regarding effects of obestatin on insulin secretion are limited and controversial as stimulation (Granata et al., 2008), inhibition (Qader et al., 2008), and lack of effect (Green et al., 2007) have been reported. Further studies are necessary to clarify this issue and the effects of obestatin on glucose-sensing neurones, insulin action and hepatic glucose production. In addition, previous studies suggest that obestatin is involved in lipid metabolism. Nagaraj et al. (2008 and 2009) reported that 8-day obestatin treatment led to 22-32% decrease of plasma triglyceride levels. Agnew et al. (2011) did not observe any changes in fasting cholesterol levels following 14-day continuous infusion with obestatin, however obestatin led to a significant 40% reduction in plasma triglyceride levels.

2.5.4.3 Growth hormone secretion

Most studies showed that neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of growth hormone (GH) in rats (Bresciani et al., 2006 and Yamamoto et al., 2007). Nevertheless, one study showed that obestatin, in some conditions, can inhibit exogenous ghrelin action on GH release (Zizzari et al., 2007). It remains to be determined whether obestatin modulates endogenous ghrelin actions.

2.5.4.4 Reproduction

Data regarding obestatin effects on reproductive function are very limited. A recent study demonstrated that obestatin may directly control porcine ovarian granulosa cells functions, stimulating proliferation and apoptosis of these cells and the secretion of progesterone (Mészárosová et al., 2008).

2.5.4.5 Gastrointestinal function

Recently, obestatin was demonstrated to stimulate the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats (Kapica et al., 2007). As with the effects of obestatin on regulation of food intake, its effects on gastrointestinal motility are involved in great controversy with most studies reporting no effect (Bassil et al., 2007; De Smet et al., 2007; Gourcerol et al., 2007; Depoortere et al., 2008 and Chen et al., 2010), and others reporting a negative effect (in gastric and jejunal motility) under basal and ghrelin-stimulated conditions (Zhang et al., 2005). Further studies should clarify this issue and its effects on gastric exocrine secretion and epithelial protection.

2.5.4.6 Cellular proliferation

Obestatin may also be able to influence cell proliferation and apoptosis. It was demonstrated that obestatin induces cell proliferation in primary cultures of human retinal epithelial cells by MEK/ERK 1/2 phosphorylation (Camiña et al., 2007) and promotes human islets cells survival through cAMP increase and involvement of AC/cAMP/PKA signaling (Granata et al., 2008).

2.5.4.7 Bone physiology

Data regarding effects of des-acyl ghrelin and obestatin on bone physiology are very limited. A recent study demonstrated that des-acyl ghrelin stimulates human osteoblasts proliferation in the absence of GHS-R1a (Delhanty et al., 2006). Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes (Lago et al., 2007).

2.5.4.8 Other effects

Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of prolactin, thyroid stimulating hormones and adrenocorticotrophic hormone in rats (Bresciani et al., 2006 and Nogueiras et al., 2007). On the other hand, a recent report provides evidence indicating that obestatin effects are functionally opposite on anxiety to that of ghrelin, while both these related peptides increase memory retention (Carlini et al., 2007). Recently, it was demonstrated that obestatin has also a sleep-promoting effect (Szentirmai and Krueger, 2006b and Szentirmai et al., 2009).

2.6 Related studies

Catalán et al. (2007) evaluated the actual presence of obestatin receptor (GPR39) mRNA in human adipose tissue and whether GPR39 expression levels are altered in obesity and obesity-associated type 2 diabetes. Omental adipose tissue biopsies obtained from 15 women were used in the study. Patients were classified as lean ($\text{BMI}=20.8\pm1.0 \text{ kg/m}^2$), obese normoglycaemic ($\text{BMI}=48.4\pm2.1 \text{ kg/m}^2$) and obese type 2 diabetic patients ($\text{BMI}=52.6\pm4.9 \text{ kg/m}^2$). Obese type 2 diabetic patients exhibited significantly lower GPR39 expression levels compared to lean ($P=0.016$) and obese normoglycaemic subjects ($P=0.008$), while no differences between lean and obese normoglycaemic patients were observed. The mRNA expression levels of GPR39 were negatively correlated to fasting glucose concentrations ($r=-0.581$, $P=0.023$), while exhibiting a positive correlation to adiponectin mRNA expression levels ($r=0.674$, $P=0.006$). The authors concluded that the reduced expression levels of GPR39 in omental adipose tissue observed in obese type 2 diabetic patients suggest an involvement of obestatin signalling in glucose homeostasis and type 2 diabetes development.

Qi et al. (2007) investigated whether plasma obestatin level is different in patients with impaired glucose regulation (IGR) and type 2 diabetes mellitus (T2DM). Forty-seven patients with T2DM, 30 subjects with IGR, and 38 sex- and age-matched normal controls participated in the study. Plasma obestatin levels were lower in patients with T2DM and IGR than in controls ($37.5\pm9.2 \text{ ng/l}$ and $39.2\pm9.7 \text{ ng/l}$ vs. $43.8\pm8.0 \text{ ng/l}$, $P=0.002$ and $P=0.039$, respectively). Decreasing concentrations of obestatin were independently and significantly associated with IGR and T2DM. Multiple logistic regression analysis revealed obestatin to be independently associated with IGR and T2DM. In a multiple linear regression analysis, only waist-to-hip ratio and homeostasis model assessment of insulin resistance were independently associated with plasma obestatin level.

Basal plasma obestatin levels were investigated in 321 normal weight and obese subjects in relation to BMI, gender, age, insulin concentrations, and type 2 diabetes (Lippl et al., 2008). Additionally, postprandial obestatin levels were determined in 20 normal weight subjects. Basal obestatin levels in females were higher compared to males (193.6 ± 5.8 vs. 140.6 ± 5.1 pg/ml). Obestatin levels correlated inversely and significantly with BMI (f: $r = -0.632$, $p < 0.001$; m: $r = -0.487$, $p < 0.001$) and basal insulin levels (f: $r = -0.536$, $p < 0.001$; m: $r = -0.320$, $p = 0.008$) in females and males. However, in a multiple regression analysis as well as in a matched comparison of a low and high insulin group no significant relationship between insulin and obestatin levels was observed in nondiabetics. On the other hand, inclusion of type 2 diabetics with higher insulin levels resulted in a significant inverse correlation. Obestatin levels were independent of age in both sexes. In patients with type 2 diabetes basal obestatin levels were not different compared to nondiabetic subjects when matched for gender, body mass index, and insulin. In normal weight subjects, postprandial obestatin levels showed a significant decrease between 60 and 90 minutes rising to basal levels thereafter.

St-Pierre et al. (2010) clarified obestatin secretion in normal subjects and in patients with type 2 diabetes in basal conditions and after a standardized meal. Five normal subjects and 5 type 2 diabetic patients were studied during infusion of saline (iv for over 5 h from -120 to +180 min). A standardized lunch was served at 0 min. Obestatin, glucose, and insulin levels were assayed at -120, -90, -60, -45, -30, -15, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min. From -120 to 0 min, obestatin levels in normal and type 2 diabetic patients were similar (area under the curve: 32.3 ± 5.6 pg/ml/min vs 31.1 ± 1.0 pg/ml/min). After the meal, circulating obestatin levels underwent a clear decrease in normal subjects (0 min: 300.6 ± 34.7 pg/ml vs nadir at 60 min: 161.8 ± 29.4 pg/ml; $p = 0.002$) but not in diabetic patients (0 min: 267.2 ± 16.5 pg/ml vs nadir at 180 min: 226.0 ± 10.5 pg/ml).

Jack, (2012) measured fasting plasma obestatin concentrations of the subjects divided in type 2 diabetes (T2DM), impaired glucose tolerance (IGT) and normal glucose tolerance (NGT) to investigate the relationship between

obestatin and fasting plasma glucose (FPG), 2 hour plasma glucose (2hPG), fasting plasma insulin (FIns), insulin resistance (IR) and plasma lipid as well as other factors in population with different glucose tolerances. Plasma obestatin levels were measured by radioimmunoassay. The relationship between plasma Obestatin levels and BMI, the homeostasis model assessment of insulin resistance (HOMA-IR), plasma glucose, insulin, blood lipids levels were also analyzed by bivariate, and multivariate regression analysis. Plasma obestatin levels in patients with IGT and T2DM were significantly reduced compared with controls (2.41 ± 0.78 ng/ ml) and (2.95 ± 0.56 ng/L) vs (3.41 ± 0.61 ng/ ml), $P = 0.01$. Plasma obestatin levels were also found to be markedly decreased in obese subjects in three groups when compared to subject with BMI 25 kg/m^2 . Plasma obestatin levels correlated negatively with systolic blood pressure (SBP), diastolic blood pressure (DBP), BMI, waist to hip ratio (WHR), FPG, 2hPG, Fins, HOMA-IR, triglycerides, LDL-C, C-reactive protein ($P < 0.01$ and $P < 0.05$) in simple regression analysis. But in a multiple regression analysis, only BMI and FPG were independently associated with plasma obestatin levels ($P < 0.01$). In non-obese groups only HOMA-IR was independently associated with plasma obestatin levels ($P < 0.01$).

Chapter 3

Materials and Methods

3.1 Study design

Case control study design.

3.2 Study population

The target population was type 2 diabetic women aged 40-65 years attending Medical Relief Center in Gaza Governorate. Healthy non diabetic women were served as controls.

3.3 Sampling and sample size

Non probability accidental sample of type 2 diabetic women, previously diagnosed according to the WHO diagnostic criteria for diabetes (World Health Organization, 2006), were selected as cases from Medical Relief Center in Gaza Governorate. Healthy non diabetic women were served as controls. Cases and controls were matched with age. The sample size was 128 women (64 type 2 diabetic women and 64 healthy non diabetic women).

3.4 Exclusion criteria

Women aged <40 and >65 years

Women with blood pressure >140/90

Pregnant women

Type 1 diabetic women

3.5 Ethical Considerations

The necessary approval to conduct the study was obtained from the local ethical committee in the Gaza Strip.

3.6 Data collection

3.6.1 Questionnaire interview

A meeting interview was used for filling in a questionnaire which designed for matching the study need for both cases and controls (Annex 1). All interviews were conducted face to face by the researcher himself. During the survey the interviewer explained any of the questions that were not clear. The questionnaire was based on the questions of a previous study with some modifications (Altawil, 2009). Most questions were the yes/no questions which offer a dichotomous choice (Backstrom and Hursh-Cesar, 1981). The validity of the questionnaire was tested by six specialists in the fields of epidemiology, public health, endocrinology and nutrition. The questionnaire was piloted with 10 patients. The questionnaire included questions on the sociodemographic data of the study population (age, education and family history), diet and drug therapy, and clinical data including duration of DM and the most important complications of diabetes.

3.6.2 Body mass index

Body mass index was calculated as the ratio of body weight in Kg/height in square meter. Women were asked to remove heavy clothes and shoses before measurement of weight and height. Medical balance (Seca Model 762, Germany) was used for weight measurement. Women with BMI=18.5–24.9 were considered to have normal weight and women with BMI \geq 30.0 were considered obese (WHO, 2000).

3.6.3 Specimen collection and biochemical analysis

Twelve hours fasting overnight venous blood samples were collected from 64 type 2 diabetic women and 64 healthy non diabetic controls. Blood samples (6 ml each) were drawn by the researcher herself, who had a Bachelor Degree of Medical Technology, into vacutainer and plastic tubes from each control and diabetic women. About 2 ml blood was placed into EDTA vacutainer tube to perform HbA1C for cases and controls. One ml blood was placed into a plastic tube contained 10 μ l protease inhibitor cocktail supplied by sigma-Aldrich Germany with catalog number (P8340) for serum obestatin assay. The remainder quantity of blood (3 ml) was placed in plastic tube for glucose, cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), urea and creatinine determination. The blood (one and 3 ml samples) was left for a while without anticoagulant to allow blood to clot. Serum samples were obtained by centrifugation at 3000 rpm for 10 minutes. Serum with protease inhibitor cocktail tubes were stored at $-30\pm5^{\circ}$ C for serum obestatin assay. However, serum analysis for glucose, lipid profile, urea and creatinine was done immediately.

3.7 Biochemical analysis

3.7.1 Determination of serum obestatin

Determination of human serum obestatin level was carried out by competitive enzyme immunoassay (ELISA) for the quantitative determination of obestatin in human serum and plasma Catalog number 48-OBEHU-E01 Size: 96 wells, Alpco diagnostics, USA.

Assay principle

This EIA kit for determination of obestatin in human plasma or serum samples is based on a competitive enzyme immunoassay using the combination of highly specific antibody to human obestatin and biotin–avidin affinity system. The 96 wells plate is coated with goat anti rabbit IgG, to which biotinylated human obestatin, human obestatin standard or samples and rabbit antihuman obestatin antibody are added for competitive immunoreaction. After incubation and plate washing, horse radish peroxidase (HRP) labeled streptavidin (SA) is

added, so that HRP labeled SA-biotinylated human obestatin-antibody complex is formed on the surface of the wells. Finally, HRP enzyme activity is determined by 3, 3',5,5'-Tetramethylbenzidine (TMB) and the concentration of human obestatin is calculated.

Composition

	Component	Form	Quantity	Main ingredient
1	Antibody Coated Plate	Microtiter plate	1 Plate (96 wells)	Goat anti rabbit IgG
2	Standard	Lyophilized powder	1 Vial (50ng)	Synthetic human obestatin
3	Labeled Antigen	Lyophilized powder	1 Vial	Biotinylated human obestatin
4	Specific Antibody	Liquid	1 Bottle (6mL)	Rabbit anti human obestatin antibody
5	SA-HRP Solution	Liquid	1 Bottle (12mL)	HRP labeled streptavidin
6	TMB Substrate	Liquid	1 Bottle (12mL)	3,3',5,5'-Tetramethylbenzidine (TMB)
7	Reaction Stopping Solution	Liquid	1 Bottle (12mL)	1M H ₂ SO ₄
8	Buffer Solution	Liquid	1 Bottle (25mL)	BSA containing saline buffer
9	Concentrated Wash Solution	Liquid	1 Bottle (25mL)	Concentrated saline
10	Adhesive Foil		3 Sheets	

Method

Note: Before starting assay, all the reagents were brought to room temperature (20-25°C) except samples. Protease inhibitor added serum and plasma samples were kept in an ice-bath after separation or during thawing from freezing and were used in as soon as possible.

Equipment required

1. Photometer for microtiter plate (plate reader), which can read extinction 2.5 at 450nm.
2. Washing device for microtiter plate and dispenser with aspiration system.
3. Micropipettes, multi-channel pipettes for 8 wells or 12 wells and their tips (20µL-1mL).
4. Test tubes (glass or polypropylene) for preparation of standard solution

5. Graduated cylinder (500mL or 1,000mL).
6. Distilled or deionized water.
7. Lint free paper towel.
8. A microplate shaker if necessary.

Preparatory work

1. Preparation of standard solution:

The Standard (lyophilized human obestatin 50ng/vial) was reconstituted with 0.5mL of Buffer Solution, which affords 100ng/mL standard solution. The reconstituted standard solution (0.1mL) was diluted with 0.2mL of Buffer Solution that yields 33.333ng/mL standard solution. The same dilution to make each standard solution of 11.111, 3.704, 1.235, and 0.412 ng/mL. Buffer Solution was used as 0 ng/mL.

2. Preparation of labeled antigen solution: Reconstitute Labeled Antigen with 6mL of Buffer Solution was reconstituted.
3. Preparation of washing solution: A volume of 25mL of Concentrated Wash Solution was diluted to 500mL with distilled or deionized water.
4. Other reagents were ready for use.

Procedure

1. Three hundred microliter of washing solution was added to each well and kept for at least 30 seconds, then the washing solution was aspirated in the wells. The plate was inverted and tapped firmly on a lint free paper towel to ensure blotting free of most residual washing solution.
2. Fifty microliter of labeled antigen solution was filled into each well first, then 20 μ L of each of standard solutions (0, 0.412, 1.235, 3.704, 11.111, 33.333, 100ng/mL) or samples was introduced and finally 50 μ L of human obestatin antibody solution was added into each well.
3. The plate was covered with Adhesive Foil and was incubated at 4°C for 18 - 20 hours with additional 30 minutes at room temperature (still or shaking).
4. After incubation, the Adhesive Foil was taken off, the contents were aspirated, then 300 μ L of washing solution was added to each well and aspirated. The wash step was repeated for total of five times with approximately 300 μ L/well of washing solution each time and finally invert the

plate and tap it firmly on a lint free paper towel to ensure blotting free of most residual washing solution.

5. One hundred microliter of SA-HRP Solution into each well was pipetted.

6. The plate with Adhesive Foil was covered and incubated at room temperature for 1 hour (still or shaking).


7. The Adhesive Foil was taken off, the wells were aspirated and washed five times as procedure 4.

8. One hundred microliter of TMB Substrate was added into each well; the plate was covered with Adhesive Foil and kept for 30minutes (still or shaking) at room temperature under a light proof condition.

9. One hundred microliter of reaction Stopping Solution was added into each well to stop coloring reaction.

10. The optical absorbance of the wells was read at 450nm.

11. Mean optical density values of wells containing standard solutions or their bound percentage (B/Bo%) to Bo wells (0 ng/mL standard as Bo) was calculated and a standard curve on a semi-logarithmic graph paper (abscissa: concentrations of standard; ordinate: optical density or B/Bo%) was plotted. The average optical density or B/Bo% of each sample was used to determine the corresponding value by simple interpolation from the standard curve.



Assay range

0.412 – 100ng/mL

3.7.2 Determination of glycohemoglobin (HbA1c) in whole blood

HbA1c was determined by the colorimetric determination of glycohemoglobin in whole blood using Stanbio Kit, Texas-USA.

Principle

A preparation of hemolyzed whole blood is mixed with a weakly binding cation exchange resin. The non-glycosylated hemoglobin HbA0 binds to the resin, leaving HbA1 free to be removed by means of a resin separator in the supernate. The percent of HbA1 is determined by measuring the absorbance values at 415 nm of the HbA1 fraction and of the total Hemoglobin fraction, calculating the ratio of absorbances (R), and comparing this ratio to that of a glycohemoglobin standard carried through the same procedure.

Results are express as HbA, but can be converted or derived as HbA1c by using a conversion factor or when using HbA1c value for the standard.

Reagents

Glycohemoglobin Ion Exchange Resin. Each tube contains 3.0 mL cation exchange resin 8 mg/dL. pH 6.9
Glycohemoglobin Lysing Reagent contains potassium cyanide 10 mmol/L and surfactants.
Glycohemoglobin Standard (Lyophilized) (1 vial) prepared from packed human erythrocytes.

Procedure**Hemolysate Preparation**

1. Five hundred microliter lysing reagent was pipetted into tubes labeled Standard (S), Unknown (U) and Control (C).
2. One hundred microliter of each was pipetted into appropriately labeled tube and mixed.

3. Tubes was allowed to stand for 5 minutes at room temperature (15-30°C) to complete hemolysis.

Glycohemoglobin separation and assay

1. Resin tubes was labeled Standard (S), Unknown (U) and Control (C).
2. One hundred microliter was pipetted of the prepared hemolysate into appropriately labeled resin tube.
3. A resin separator was positioned in the tube so rubber sleeve is approximately 1-2 cm above liquid level.
4. Tubes were mixed on a hematology rocker for 5 minutes. Alternatively tubes may be mixed by hand if held above the resin.
5. At the end of the 5 minute mixing, resin separator was pushed into tube until resin is firmly packed in bottom of the 13mm tube.
6. Each supernate was poured directly into separate cuvettes for absorbance measurements.
7. Absorbance was read (Agly) of Standard, Unknown and Control vs. water at 415 nm within 60 minutes.

Total hemoglobin assay

1. Five milliliter deionized water was pipetted into tubes labeled Standard (S), Unknown (U) and Control (C).
2. Twenty microliter of hemolysate was pipetted into appropriately labeled tube and mixed well and transferred to cuvette for absorbance reading.
3. Absorbance (Atot) of Standard was read, Unknown and Control vs. water at 415 nm within 60 minutes.

Calculation

For each Standard and Unknown calculate the ratio (R) of the glycohemoglobin absorbance to the hemoglobin absorbance as follows:

$$(R) = Agly / Atot$$

$$\text{Hemoglobin (\%)} = \frac{(R) \text{ Unknown} \times \text{Hemoglobin Standard (\%)}}{(R) \text{ Standard}}$$

Results may also be reported as HbA1c when compared to the reference A1c method, the Stanbio method showed a 98% correlation with an equation of:


$$Y \text{ (A1c value)} = 0.838 \times (\text{Stanbio value}) - 0.732$$

The value obtained by the Stanbio method may be converted to Calculated A1c value by use of this formula. For a direct calculated A1c value, the value of the standard may be changed to 7.6% in lieu of the 10.0% and the results will be A1c values.

3.7.3 Determination of serum glucose

Principle

Determination of glucose after enzymatic oxidation by glucose oxidase. The colorimetric indicator is quinoneimine, which is generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of peroxidase.



POD



Reagents

Reagent	Concentration
Phosphate buffer (pH 7.5)	250 mmol/l
Phenol	5 mmol/l
4-Aminoantipyrine	0.5 mmol/l
Glucose oxidase (GOD)	≥ 15 ku/l
Peroxidase (POD)	≥ 1 ku/l
Standard	100 mg/dl

Assay procedure

Wavelength: 500 nm

Optical path: 1 cm

Temperature: 37 °C

Measurement: Against reagent blank.

- 10 µl of standard (sample or control) was added to 1ml of the reagent and mixed well.
- The mixture was incubated for 10 min at 37 °C.
- The absorbance was measured within 60 min.

Calculation

$$\text{Glucose [mg / dl]} = \frac{\Delta A \text{ sample} \times \text{concentration of standard}}{\Delta A \text{ standard}}$$

Reference value (fasting glucose)

(Palestinian clinical laboratory tests guide, PCLTG, 2005)

Child	60 – 100 mg/dl
Adult	70 – 110 mg/dl

3.7.4 Determination of serum cholesterol


Enzymatic colorimetric method for the quantitative determination of total cholesterol in serum or plasma, using Diasys Diagnostic Systems, Germany.

Principle

Determination of cholesterol after enzymatic hydrolysis and oxidation. The colorimetric indicator is quinoneimine which is generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of peroxidase.

CHE

Cholesterol ester + H₂O → cholesterol + fatty acid



Reagents

Concentrations are those in the final test mixture.

Reagent	Concentration
Good's buffer (pH 6.7)	50 mmol/l
Phenol	5 mmol/l
4- Aminoantipyrine	0.3 mmol/l
Cholesterol esterase (CHE)	≥ 200 u/l
Cholesterol oxidase (CHO)	≥ 100 u/l
Peroxidase (POD)	≥ 3 ku/l
Standard	200 mg/dl

Assay procedure

Wavelength: 500 nm

Optical path: 1cm

Temperature: 37 °C

Measurement: against reagent blank.

- Ten µl of standard (sample or control) was added to 1ml of working reagent and mixed well.
- The mixture was incubated for 5 min at 37 °C.
- The absorbance was measured within 60 min.

Calculation

$$\text{Cholesterol (mg/dl)} = \frac{\Delta A \text{ sample} \times \text{concentration of standard}}{\Delta A \text{ standard}}$$

Reference value


Child (desirable)	< 170 mg/dl
Adult (desirable)	<200 mg/dl

3.7.5 Determination of serum triglycerides

Enzymatic colorimetric method for the quantitative determination of total Cholesterol in serum or plasma, using Diasys Diagnostic Systems, Germany.

Principle

Determination of triglycerides after enzymatic splitting with lipoprotein lipase. Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4-chlorophenol by hydrogen peroxide under the catalytic action of peroxidase.



Reagents

Concentrations are those in the final test mixture.

Reagent	Concentration
Cood's buffer (pH 7.2)	50 mmol/l
4-Chlorophenol	4 mmol/l
ATP	2 mmol/l
Mg ²⁺	15 mmol/l

Glycerokinase	(GK)	≥ 0.4 KU/l
Peroxidase	(POD)	≥ 2 KU/l
Lipoprotein lipase	(LPL)	≥ 2 KU/l
4-Aminoantipyrine		0.5 mmol/l
Glycerol-3-phosphate-oxidase (GPO)		≥ 0.5 KU/l
Standard		200 mg/dl

Assay Procedure

Wavelength: 500 nm

Optical path: 1 cm

Temperature: 37 °C

Measurement: Against reagent blank.

- Ten µl of standard (sample or control) was added to 1ml of working reagent and mixed well.
- The mixture was incubated for 5 min at 37 °C.
- The absorbance was measured within 60 min.

Calculation

$$\text{Triglycerides [mg / dl]} = \frac{\Delta A \text{ sample} \times \text{concentration of standard}}{\Delta A \text{ standard}}$$

Reference value

Child (desirable)	30 - 150 mg/dl
Adult (desirable) M	40 - 160 mg/dl
F	35 - 135 mg/dl

3.7.6 Determination of serum high density lipoprotein cholesterol (HDL-C)

Liquid HDL-C precipitant for the determination of HDL-C Cholesterol using Diasys Diagnostic Systems, Germany.

Principle

Chylomicrons, VLDL-C and LDL-C were precipitated by adding phosphotungstic acid and magnesium ions to the sample. Centrifugation leaves only the HDL-C in the supernatant, their cholesterol content is determined enzymatically using cholesterol reagent.

Reagents

Reagent	Concentration
Monoreagent contain: Magnesium chloride	1.4 mmol/l
Phosphotungstic acid	8.6 mmol/l
Cholesterol standard	200 mg/dl

Assay procedure

1- Precipitation

- Two hundred µl of standard (sample or control) were added to 500 µl of the precipitation reagent and mixed well.
- The mixture was allowed to stand for 15 min at room temperature, and then centrifuged for 20 min at 4000 rpm.

2- Cholesterol determination

Wavelength: 500 nm

Optical path: 1cm

Temperature: 37 °C

Measurement: against reagent blank.

- One hundred µl of the supernatant of standard (sample or control) was added to 1ml of the cholesterol reagent and mixed well.
- The mixture was incubated for 5min at 37 °C.
- The absorbance was measured within 45 min.

Calculation

$$\text{HDL-C (mg/dl)} = \frac{\Delta A \text{ sample} \times \text{concentration of standard}}{\Delta A \text{ standard}}$$

Reference value

Child	37 – 75 mg/dl
Adult: M	35 – 65 mg/dl
F	35 – 80 mg/dl

3.7.7 Determination of serum low density lipoproteins cholesterol (LDL-C)

LDL-C can be calculated using the empirical relationship of Friedewald.

Principle

The ultracentrifugal measurement of LDL-C is time consuming and expensive and requires special equipment. For this reason, LDL-C is most commonly estimated from quantitative measurements of total and HDL-C and plasma triglycerides (TG) using the empirical relationship of Friedewald.

The Equation


$$\text{LDL-C} = \text{Total Cholesterol} - \text{HDL-C} - \text{TG}/5$$


3.7.8 Determination of serum urea

Serum Urea was determined by urease - glutamate dehydrogenase (GDH)/UV method using BioSystems kit, Spain.

Principle

Urea in the sample is consumed, by means of the coupled reactions described below. The decrease of NADH can be measured photometrically at 340 nm.





Reagents

Concentrations are those in the final test mixture.

Reagent	Concentration
R1: TRIS	120 mmol/l
2- Oxoglutarate	7 mmol/l
ADP	0.6 mmol/l
Urease	≥ 0.6 ku/l
GLDH	≥ 1 ku/l
R2: NADH	0.25 mmol/l
Standard	50 mg/dl

Assay procedure

The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.

Wavelength: 340 nm

Optical path: 1cm

Temperature: 37 °C

Measurement: against distilled water.

- 10 µl of standard (sample or control) was added to 1ml of working reagent and mixed well.
- The mixture was incubated for 30 sec then absorbance (A1) was recorded.
- After exactly further 60 sec the absorbance (A2) was measured.

Calculation

$\Delta A = (A1 - A2)$ sample or standard

Urea (mg/dl) = $\frac{\Delta A \text{ sample} \times \text{concentration of standard}}{\Delta A \text{ standard}}$

Reference value

(PCLTG, 2005)

Child	5 - 30 mg/dl
Adult	13 - 43 mg/dl

3.7.9 Determination of serum creatinine

Serum Creatinine was determined by Alkaline Picrate method using BioSystems kit, Spain.

Principle

Creatinine forms a colored orange-red complex in an alkaline picrate solution. The difference in absorbance at fixed times during conversion is proportional to the concentration of creatinine in the sample.

Creatinine + Picric acid \longrightarrow creatinine picrate complex

Reagents

Concentrations are those in the final test mixture.

Reagent	Concentration
R1: Sodume hydroxide (pH approx. 13)	0.16 mol/l
R2: Picric acid (pH approx. 1.2)	4.0 mmol/l
Standard	2.0 mg/dl

Assay procedure

The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.

Wavelength: 490 nm

Optical path: 1cm

Temperature: 37 °C

Measurement: against distilled water.

- 50 µl of standard (sample or control) was added to 1ml of working reagent add and mixed well.

- The Mixture was incubated for 60 sec then absorbance(A1) was recorded.
- After exactly further 120 sec the absorbance (A2) was measured.

Calculation

$\Delta A = (A1 - A2)$ sample or standard

Creatinine (mg/dl) = $\frac{\Delta A \text{ sample} \times \text{concentration of standard}}{\Delta A \text{ standard}}$

Reference value (PCLTG, 2005)

Infant	0.2 – 0.4 mg/dl
Child	0.3 - 0.7 mg/dl
Adolescent	0.5 - 1.0 mg/dl
Adult: M	0.6 - 1.2 mg/dl
F	0.5 -1.1 mg/dl

3.8 Statistical analysis

Data were computer analyzed using SPSS/ PC (Statistical Package for the Social Science Inc. Chicago, Illinois USA, version 18.0) statistical package.

- Simple distribution of the study variables and the cross tabulation were applied.
- Chi-square (χ^2) was used to identify the significance of the relations, associations, and interactions among various variables. Yates's continuity correction test, $\chi^2_{\text{(corrected)}}$, was used when not more than 20% of the cells had an expected frequency of less than five and when the expected numbers were small.
- The independent sample t-test procedure was used to compare means of quantitative variables by the separated cases into two qualitative groups such as the relationship between cases and controls obestatin hormone.
- Pearson's correlation test was applied.
- The results in all the above mentioned procedures were accepted as statistical significant when the p-value was less than 5% ($p < 0.05$).
- Range as minimum and maximum values was used.
- The percentage difference was calculated according to the formula: Percentage difference equals the absolute value of the change in value, divided by the average of the 2 numbers, all multiplied by 100.
Percent difference = $(| (V1 - V2) | / ((V1 + V2)/2)) * 100$.
- Microsoft Excel program version 11.0 was used for correlation graph plotting, between obestatin level and HbA1C, glucose and triglyceride levels.

Chapter 4

Results

4.1 Sociodemographic data of the study population

The present study is a case control design. The study population comprised 64 diabetic women (case group) and 64 healthy control women. Table 4.1 summarizes the sociodemographic data of the study population. Age classification showed that 28 (43.7%) controls and 27 (42.2%) cases were 40-50 years old. Age group 51-60 years comprised 24 (37.5%) controls and 26 (40.6%) cases. Controls and cases aged >60 years old were 12 (18.8%) and 11 (17.1%), respectively. The difference between controls and cases in term of age distribution was not significant ($\chi^2=0.142$, $P=0.931$). The mean ages of controls and cases were 52.7 ± 8.9 and 52.9 ± 8.3 years old with ranges of 40-65 and 40-64 years, respectively. The independent sample t-test also showed no significant difference between mean ages of controls and cases ($t=0.113$, $P=0.911$). Analysis of the educational status of the study population showed that 13 (20.3%) controls and 20 (31.3%) cases had diploma or university degree, 14 (21.9%) and 14 (21.9%) had finished secondary school, 25 (39.1%) and 16 (25.0%) had finished preparatory school, 3 (4.7%) and 8 (12.5%) had passed primary school, and 9 (14.1%) and 6 (9.4%) were illiterate, respectively. The difference between various educational levels of controls and cases was not significance ($\chi^2_{(corrected)}=4.409$, $P=0.353$). Regarding family history, 41 (64.1%) controls and 52 (81.2%) cases had family history of diabetes whereas 23 (35.9%) and 12 (18.8%) had not. The difference between the two groups was significance ($\chi^2=4.758$, $P=0.029$), indicating that family history is associated with diabetes.

Table 4.1. Sociodemographic data of the study population

Character	Controls (n=64)		Cases (n=64)		test		P-value
	No.	%	No.	%			
Age (Year)							
40-50	28	43.7	27	42.2	χ^2	0.142	0.931
51-60	24	37.5	26	40.6			
>60	12	18.8	11	17.1			
Mean \pm SD	52.7 \pm 8.9		52.9 \pm 8.3		t	0.113	0.911
Range (min-max)	40-65		40-64				
Education							
University or diploma	13	20.3	20	31.3	χ^2	4.409	0.353*
Secondary	14	21.9	14	21.9			
Preparatory	25	39.1	16	25.0			
Primary	3	4.7	8	12.5			
Illiterate	9	14.1	6	9.4			
Family history							
Yes	41	64.1	52	81.2	χ^2	4.758	0.029
No	23	35.9	12	18.8			

*P-value of $\chi^2_{(\text{corrected})}$ test

P>0.05: not significant, P<0.05: significant.

4.2 Diet and drug therapy among the study population

Table 4.2 illustrates diet and drug therapy among the study population. The number of controls and cases on diet were 16 (25.0%) and 30 (46.9%), respectively whereas those who were not were 48 (75.0%) and 34 (53.1). The difference between the two groups was significant ($\chi^2=6.651$, P=0.010). Almost all cases 63 (98.4%) were administered the antidiabetic drug Glucophage.

Table 4.2. Diet and drug therapy among the study population

Character	Controls (n=64)		Cases (n=64)		χ^2	P-value
	No.	%	No.	%		
Diet						
Yes	16	25.0	30	46.9	6.651	0.010
No	48	75.0	34	53.1		
Therapy drug						
Glucophage	-	-	63	98.4	NA	NA
Glucophage and Daonail	-	-	1	1.6		

P<0.05:significant. NA: Non Applicable.

4.3 Distribution of diabetic patients by the duration of the disease

Table 4.3 demonstrates the distribution of diabetic patients by the duration of the disease. Patients with diabetes since less than 5 years were 38 (59.4%), whereas those with diabetic duration of 5-10 years were 14 (21.9%). The rest of patients 12 (18.7%) had diabetes for more than 10 years.

Table 4.3. Distribution of diabetic patients (n=64) by the duration of the disease

Duration of diabetes (Year)	No.	%
< 5	38	59.4
5-10	14	21.9
>10	12	18.7

4.4 Self-reported complications of the study population

The main self-reported complications among diabetic patients and controls are summarized in Table 4.4. The percentages of retinopathy and neuropathy were higher in cases compared to controls (37.5 and 43.8% vs 12.5 and 14.1%, respectively) with statically significant differences ($\chi^2_{(corrected)}=10.667$, $P=0.001$ and $\chi^2_{(corrected)}=13.724$, $P=0.000$, respectively). However, no significant difference was found between cases (6.3%) and controls (1.6%) in term of CVD ($\chi^2_{(corrected)}=0.833$, $P=0.361$).

Table 4.4. The main self-reported complications among the study population (n=128)

Complication	Control (n=64) n (%)	Cases (n=64) n (%)	χ^2	P-Value
Retinopathy				
Yes	8(12.5)	24(37.5)	10.667	0.001
No	56 (87.5)	40 (62.5)		
CVD**				
Yes	1 (1.6)	4(6.3)	0.833	0.361*
No	63 (98.4)	60 (93.8)		
Neuropathy				
Yes	9(14.1)	28(43.8)	13.724	0.000
No	55 (85.9)	36 (56.2)		

*P-value of $\chi^2_{(corrected)}$ test. **CVD: Cardiovascular diseases. $P>0.05$: not significant, $P<0.05$: significant.

4.5 Self-reported complications among patients in relation to the duration of diabetes

Self-reported complications among patients in relation to the duration of diabetes is provided in Table 4.5. In general, the longer the duration of diabetes mellitus, the higher the percentage of self-reported complications

among patients. This positive relationship was statically significant for retinopathy ($\chi^2=6.210$, $P=0.045$) and neuropathy ($\chi^2=6.934$, $P=0.031$). On the other hand, such relationship was not statically significant for CVD ($\chi^2_{(corrected)}=0.267$, $P=0.875$).

Table 4.5. Self-reported complications among patients in relation to the duration of diabetes

Complication	Duration of diabetes (Year)			χ^2	P-Value
	< 5 (n=38) n (%)	5-10 (n=14) n (%)	> 10 (n=12) n (%)		
Retinopathy (n=24)	9 (23.7)	7 (50.0)	8(66.7)	6.210	0.045
CVD** (n=4)	2 (5.3)	1 (7.1)	1 (8.3)	0.267	0.875*
Neuropathy (n=28)	11(28.9)	8(57.1)	9(75.0)	6.934	0.031

*P-value of $\chi^2_{(corrected)}$ test. **CVD: Cardiovascular diseases. $P>0.05$: not significant, $P<0.05$: significant.

4.6 Anthropometric measurements of the study population

Table 4.6 shows the anthropometric measurements of the study population. The mean weight of controls was 88.3 ± 21.6 kg compared to 88.5 ± 17.4 kg of cases. The weight difference was not significant ($t=0.173$ and $P=0.864$) with % difference=0.2. There was also a none significant difference in the mean height of cases compared to controls (1.58 ± 0.06 vs. 1.59 ± 0.06 m, % difference=0.6, $t=0.894$ and $P=0.375$). Therefore, no significant difference was found in BMI of cases versus controls (35.2 ± 6.5 vs. 34.4 ± 7.7 , % difference=2.3, $t=0.281$ and $P=0.780$).

Table 4.6. Anthropometric measurements of the study population

Anthropometric measurement	Controls (n=64) mean±SD	Cases (n=64) mean±SD	% difference	t	P-value
Weight (kg)* (min-max)	88.3±21.6 (60-135)	88.5±17.4 (59-140)	0.2%	0.173	0.864
Height (m)** (min-max)	1.59±0.06 (1.49-1.75)	1.58±0.06 (1.46-1.71)	0.6%	0.894	0.375
BMI*** (min-max)	34.4±7.7 (24-53)	35.2±6.5 (25-59)	2.3%	0.281	0.780

*Kg: kilogram,** m: meter. ***BMI: Body mass index: Normal=18.5-24.9, Obese≥30 (WHO, 2000).All values are expressed as mean ±SD. P>0.05: not significant.

4.7 Serum obestatin levels of the study population

The average serum obestatin levels in controls and cases is presented in Table 4.7. There was a significant decrease in the mean level of obestatin in cases compared to controls (3.4±0.8 vs. 4.1±1.5 ng/ml, % difference=18.6, t=2.328 and P=0.023).

Table 4.7. Serum obestatin of the Study population

Parameter	Controls (n=64) mean±SD	Cases (n=64) mean±SD	% difference	t	P-value
obestatin(ng/ml) (min-max)	4.1±1.5 (2.2-7.3)	3.4±0.8 (1.8-4.8)	18.6	2.328	0.023

Assay range:0.412-100 ng/mL

P<0.05: significant.

4.8 HbA1c and glucose of the study population

As indicated in Table 4.8, the mean HbA1c and glucose levels in cases were significantly higher than that in controls (6.4±0.9% and 190.7±86.7 mg/dl vs. 4.7±0.6% and 101.6±21.0 mg/dl, % difference= 30.6 and 60.9, t=9.136 and 5.726, P=0.000).

Table 4.8. HbA1c and glucose of the Study population

Parameter	Controls (n=64) mean±SD	Cases (n=64) mean±SD	% difference	t	P- value
HbA1c (%) (<i>min-max</i>)	4.7±0.6 (3.8-6.0)	6.4±0.9 (5.1-8.4)	30.6	9.136	0.000
glucose (mg/dl) (<i>min-max</i>)	101.6±21.0 (71-154)	190.7±86.7 (84-472)	60.9	5.726	0.000

Reference range: 4-6% and 70-115mg/dL

P<0.05: significant.

4.9 Serum lipid profile of the study population

Table 4.9 illustrates serum lipid profile of the study population including cholesterol, triglycerides, HDL-C and LDL-C of cases and controls. The average levels of cholesterol and triglycerides were found to be higher in cases (194.8±44.7 and 183.3±80.0 mg/dl, respectively) compared to controls (188.1±38.3 and 122.4±42.9 mg/dl, respectively) with % differences of 3.5 and 39.8%, respectively). However, this increase was statistically significant for triglycerides (t=3.841, P=0.000). No statistically significant change was found for LDL-C between cases and controls. On the other hand, HDL-C was significantly lower in cases compared to controls (40.7±11.2 vs. 47.2±12.0 mg/dl, % difference=14.8, t=2.228 and P=0.030).

Table 4.9. lipid profile of the Study population

Parameter	Controls (n=64) mean±SD	Cases (n=64) mean±SD	% difference	t	P-value
Cholesterol (mg/dl) (min-max)	188.1±38.3 (136-273)	194.8±44.7 (116-295)	3.5	0.640	0.524
Triglycerides (mg/dl) (min-max)	122.4±42.9 (67-265)	183.3±80.0 (75-391)	39.8	3.841	0.000
LDL-C (mg/dl) * (min-max)	116.5±37.1 (61-203)	115.3±36.0 (39-191)	1.0	0.101	0.920
HDL-C (mg/dl) ** (min-max)	47.2±12.0 (24-68)	40.7±11.2 (21-68)	14.8	2.228	0.030

*LDL-C: Low density lipoprotein cholesterol, **HDL-C: High density lipoprotein cholesterol. All values are expressed as mean ±SD. P>0.05: not significant, P<0.05: significant.

4.10 Serum urea and creatinine of the study population

Serum urea and creatinine concentrations of the study population are clarified in Table 4.10. There was a border line significant increase in urea concentration in cases compared to controls (26.0±8.1 vs 23.1±3.7mg/dl, % difference=11.8, t=1.871, P=0.066). However, such increase was not statistically significant for creatinine (0.74±0.2 vs 0.73±0.1 mg/dl, % difference= 1.4, t= 0.108, P= 0.914).

Table 4.10. Serum urea and creatinine concentration of the study population

Parameter (mg/dl)	Controls (n=64) mean±SD	Cases (n=64) mean±SD	% difference	t	P-value
Urea Range (min –max)	23.1±3.7 (17.0-32.0)	26.0± 8.1 (11.0-58.0)	11.8	1.871	0.066
Creatinine Range (min –max)	0.73±0.1 (0.50-0.90)	0.74±0.2 (0.50-1.70)	1.4	0.108	0.914

Reference range: urea=15-43 mg/dl (Thomus, 1998) and creatinine=0.6-1.1 mg/dl(Newman and Price, 1999).

4.11 Obestatin levels in relation to BMI of the study population

Obestatin level in relation to BMI of the study population is presented in Table 4.11. The Pearson correlation test showed that the higher the BMI, the lower the level of obestatin. However, this negative correlation was not statistically significant ($r=-0.068$, $P= 0.590$).

Table 4.11. Obestatin levels in relation to BMI of the study population

	Obestatin	
	Pearson correlation (r)	P-value
BMI*	-0.068	0.590

* Women with BMI=18.5–24.9 were considered to have normal weight, Women with BMI≥30.0 were considered obese (WHO, 2000). $P>0.05$: not significant.

4.12 Obestatin levels in relation to HbA1c and glucose of the study population

Table 4.12 and Figures 4.1 and 4.2 present the relationship between obestatin level with HbA1c and glucose of the study population. Obestatin

showed significant negative correlation with HbA1c and glucose ($r=-0.320$, $P=0.009$ and $r=-0.469$, $P=0.000$, respectively).

Table 4.12. Obestatin levels in relation to HbA1c and glucose of the study population

(mg/dl)	Obestatin	
	Pearson correlation (r)	P-value
HbA1c	-0.320	0.009
Glucose	-0.469	0.000




Figure 4.1. Correlation between obestatin hormone level with HbA1c of the study population.




Figure 4.2. Correlation between obestatin hormone level with fasting blood glucose level of the study population.

4.13 Obestatin levels in relation to lipid profile of the study population

The relationship between obestatin and lipid profile of the study population is demonstrated in Table 4.13. The Pearson correlation test showed that with decreasing obestatin levels there are increases in cholesterol, triglycerides and LDL-C levels. Such negative correlation was significant only for triglycerides (Figure 4.3, $r=-0.275$, $P=0.026$). On the other hand, there is a positive correlation between obestatin level and HDL-C and this correlation was also not significant ($r=0.024$, $P=0.848$).

Table 4.13. Obestatin levels in relation to lipid profile of the study population

Lipid Profile (mg/dl)	Obestatin	
	Pearson correlation (r)	P-value
Cholesterol	-0.175	0.164
Triglycerides	-0.275	0.026
*LDL-C	-0.090	0.474
**HDL-C	0.024	0.848

$P>0.05$: not significant. *LDL-C: Low density lipoprotein cholesterol, **HDL-C: High density lipoprotein cholesterol.




Figure 4.3. Correlation between obestatin hormone level with triglyceride level of the study population.

4.14 Obestatin levels in relation to urea and creatinine of the study population

As illustrated in Table 4.14, there were no significant positive correlations between obestatin levels and urea and creatinine concentrations ($r=0.000$, $P=0.997$ and $r=0.209$, $P=0.096$, respectively).

Table 4.14. Obestatin levels in relation to urea and creatinine of the study population

(mg/dl)	Obestatin	
	Pearson correlation (r)	P-value
Urea	0.000	0.997
Creatinine	0.209	0.096

Chapter 5

Discussion

Diabetes mellitus has in the last decade become a global problem. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. There are more women with diabetes than men (Wild et al., 2004). Despite its high prevalence and the subsequent health problems, there are under-diagnosis and under-reporting of diabetes mellitus in the Gaza Strip. Biochemical tests of the disease were restricted to monitoring blood glucose level when the patient visits the clinic. Recently, few studies have been focused on the determination of leptin, insulin and ghrelin in type 2 diabetic patients in Gaza Strip (Altawil, 2009 and Abu Snayma, 2012). However, no previous study investigated the role of the novel hormone obestatin in diabetes mellitus. Therefore, the present work is the first to assess obestatin status in type 2 diabetic women from Gaza.

5.1 Family history and diet among the study population

The Chi square test showed that the number of cases who had family history of diabetes was significantly higher than that of controls. This indicates that family history is associated with type 2 diabetes. Such finding is in agreement with that obtained by Annis et al., (2005); Pijl et al., (2009) and Abu Mustafa, (2011) who reported that family history is a risk factor for type 2 diabetes. Although there was a significant association between diabetes and diet, about half of the patients were not on diet. Previous work carried out in Gaza Strip showed such significant association (Altawil, 2009 and Abu Mustfa). This necessitates launching of educational programs to show the importance of diet in controlling the disease. Watkins (2003) reported that healthy eating is

the cornerstone of diabetic treatment, and control of the diet should always be the first treatment offered to Type 2 diabetic patients before drugs are considered. In this context, the most common used antidiabetic drug among type 2 diabetic patients in Gaza is glucophage.

5.2 Diabetes duration and Self-reported complications

The finding that more than half of patients had diabetes since less than 5 years do confirm the idea that type 2 diabetes has long asymptomatic pre-clinical phase which frequently goes undetected. At the time of diagnosis, the patient could have one or more diabetes complications i.e. there is a latent phase before diagnosis of Type 2 diabetes. During this period of undiagnosed disease, risk factors for diabetic micro- and macrovascular complications are markedly elevated and diabetic complications are developing (Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2003 and Watkins, 2003). The relation between diabetes duration and self-reported complications confirmed this view. However, this point still needs further investigation. The most self-reported symptoms among diabetic patients were neuropathy and retinopathy. The prevalence of such symptoms was positively associated with the progress of the disease i.e. the longer the duration of diabetes mellitus, the higher the percentage of self-reported complications among patients. Several studies reported similar diabetic complications with increasing rates upon disease progress (Savage, 1996, Dyck et al., 2002, Marshall, 2006 and The National Eye Institute, 2006, Altawil, 2009 and Abu Sunayma, 2012).

5.3 Diabetes and body mass index

Body mass index provides a reliable indicator of body fatness for most people and it is used to screen for weight categories that may lead to health problems (CDC, 2007). Therefore, obesity is commonly defined as a BMI of 30 kg/m^2 or higher. This definition distinguishes obesity from being pre-obese or overweight, which is classified as a BMI of 25 kg/m^2 but less than

30 kg/m² (WHO, 2000). In the present study, both controls and cases were obese. This masked the prospective significant association between BMI and diabetes which was mentioned by Marshall (2006) and Yassin et al. (2011). Nevertheless, matching this confounder factor may reveal the real status of obestatin in diabetic patients regardless of their body mass index.

5.4 Serum obestatin of the study population

Result presented in this study revealed that the mean level of obestatin was significantly decreased in type 2 diabetic women compared to healthy non diabetic controls. This finding is in agreement with that observed by Catalán et al. (2007); Qi et al. (2007); St-Pierre et al. (2010) and Jack, (2012). On the other hand, Lippl et al. (2008) reported that basal obestatin levels in patients with type 2 diabetes were not different compared to nondiabetic subjects. This contradiction may be explained on basis of different sample size, gender, age, BMI and pre- or postprandial periods. Therefore, well-controlled human studies collecting multiple measures of obestatin before and after a meal are needed. In addition, a better understanding of the biological mechanism of action of obestatin, i.e., through identification of its receptor, could help to explain these findings.

5.5 HbA1c and glucose of the study population

As indicated in the present results, the mean HbA1c and glucose levels in cases were significantly higher than that in controls. Similar results were obtained by Qi et al. (2007) and Yassin et al. (2011) who found that type 2 diabetic patients had higher fasting glucose and HbA1C levels than non-diabetics. In diabetes, prolonged hyperglycemia superdrives nonenzymatic protein glycation, which forms reversible Schiff bases and Amadori compounds. A series of further complex molecular rearrangements then yield irreversible advanced glycosylated end-products (AGEs). AGEs accumulate in the circulating blood and in various tissues (Furth, 1997). It is reported that the

levels of HbA1c in the blood reflect the glucose levels to which the erythrocyte has been exposed during its lifespan (Goldstein, 2004). Therefore, the HbA1c test is attractive as it measures chronic glycaemia, rather than instantaneous blood glucose levels. HbA1c has been used as an objective marker of average glycaemic control for many years, has an accepted place in the monitoring of patients with diabetes, and is relied on for significant management decisions, such as initiation of insulin therapy (d'Emden et al., 2012). In the present study, the Pearson correlation test showed negative significant correlations between obestatin levels and HbA1c and glucose. Similar result was documented by Qi et al. (2007) and Lippl et al.(2008). This negative relationship reflects the change of the glycemic parameter with obestatin and suggests an involvement of obestatin signalling in glucose homeostasis and type 2 diabetes development. This point needs further investigation.

5.6 lipid profile of the study population

The present results demonstrate significant increase in triglyceride levels of cases compared to controls. On the other hand, HDL-C level was significantly decreased in cases. Elevation of triglycerides in diabetic patients was documented by several authors (Chen et al., 2009; Katsiki et al., 2011 and Al-Hakeim and Ali 2012). The general increase levels of serum lipids in diabetic patients may be mainly attributed to increase in the mobilization of free fatty acids from fat depots, since elevation of insulin inhibits the hormone sensitive lipase. Then, excess fatty acids in serum are converted into triglycerides, phospholipids and cholesterol in liver (Scheen, 2003). The Pearson correlation test showed negative significant correlation between obestatin and triglycerides level. Similar finding was observed by Nagaraj et al. (2008 and 2009) and Agnew et al. (2011). It was reported that obestatin is a metabolic hormone capable of binding to GPR39 receptor to regulate the functions of adipose tissues (Zahng, 2008). In this context, Miegueu et al. (2011) showed that fatty acid uptake was increased three- to fourfold in a

concentration-dependent manner with obestatin. Therefore, the decreased level of obestatin observed in the present study is expected to increase serum triglycerides in diabetic patients.

5.7 Urea and creatinine concentrations of the study population

Data provided in the present study showed no significant increase in urea and creatinine concentrations in diabetic patients compared to controls. Similar results were documented by Altawil (2009) and Abu Snayma. Urea is formed by the liver as an end product of protein breakdown and creatinine is a waste product that is normally filtered from the blood and excreted with the urine. Creatinine and urea are markers of the kidney function and changes in their levels are indicating renal diseases (Debra Manzella, 2008). Therefore, the results indicated that many of the studied diabetic patients are still in the early stages of the disease. This was obvious in the finding that more than half of the patients had diabetes since less than 5 years. However, it was difficult to determine the onset of such changes in urea and creatinine concentrations and this may lead to controversial results (Varghese et al., 2001 and El Meligi et al., 2003). Therefore, the creatinine levels must be watched carefully to determine how much function the kidneys have and this does vary slightly.

Chapter 6

Conclusions and Recommendations

6.1 Conclusions

- The mean ages of controls and cases were 52.7 ± 8.9 and 52.9 ± 8.3 years.
- Type 2 diabetes was found to be associated with family history and diet.
- More than half of patients had diabetes since less than 5 years.
- The main self-reported complications among patients were neuropathy, retinopathy and cardiovascular disease. The longer the duration of diabetes, the higher the prevalence of self-reported complications.
- The mean level of serum obestatin was significantly lower in diabetic women compared to healthy non diabetic controls (3.4 ± 0.8 ng/ml vs. 4.1 ± 1.5 ng/ml, $P=0.023$).
- The mean HbA1c and glucose levels in cases were significantly higher than that in controls (6.4 ± 0.9 and 190.7 ± 86.7 vs 4.7 ± 0.6 and 101.6 ± 21.0) with $P=0.000$. The Pearson correlation test showed negative significant correlations between obestatin levels and HbA1c and glucose ($r=-0.320$, $P=0.009$ and $r=-0.469$, $P=0.000$, respectively).
- The average level of triglycerides was significantly increased in diabetic women (183.3 ± 80.0 mg/dl) compared to controls (122.4 ± 42.9 mg/dl) with $P=0.000$. On the other hand, HDL-C was significantly lower in cases (40.7 ± 11.2 vs. 47.2 ± 12.0 mg/dl, % difference=14.8 and $t=2.228$, $P=0.030$). The Pearson correlation test showed negative significant correlations between obestatin levels and triglycerides levels ($r=-0.275$, $P=0.026$).

6.2 Recommendations

- Assessment the status of obestatin hormone in diabetes could constitute a promising therapy of the disease. In this context, multiple measures of obestatin in pre- and post-prandial periods are needed.
- Launching of health education programs on diabetes particularly among women with family history of diabetes and those who are not on diet are highly recommended.
- Regular visits to neurological and optical clinics to take early steps to avoid and manage diabetic complications concerning diabetic neuropathy and retinopathy.
- Further research is highly recommended on obestatin and the development of diabetes in terms of HbA1c and glucose.

Questionnaire

I am a researcher / Mona M. Hamam (Master student/ The Islamic University of Gaza) will be very grateful if you help me in completing this study which focuses on the role of a novel hormone obestatin in type 2 diabetes in women from Gaza Governorate, Gaza strip.

Personal data	
Tel. No.	
Name(<i>Optional</i>)	
Age	
Education	<input type="checkbox"/> University or diploma <input type="checkbox"/> Secondary school <input type="checkbox"/> Preparatory school <input type="checkbox"/> Primary school <input type="checkbox"/> illiterate
Family history of diabetes	<input type="checkbox"/> Yes <input type="checkbox"/> No
BMI	Weight: Kg Height: cm
Diet	<input type="checkbox"/> Yes <input type="checkbox"/> No
Clinical data (<i>Only for diabetic patients</i>)	
Age at diagnosis	
Duration of diabetes	
Type of drug used	
Complications	
Retinopathy	<input type="checkbox"/> Yes <input type="checkbox"/> No
Cardiovascular diseases	<input type="checkbox"/> Yes <input type="checkbox"/> No
Neuropathy	<input type="checkbox"/> Yes <input type="checkbox"/> No
Recurrent infections	<input type="checkbox"/> Yes <input type="checkbox"/> No
Skin lesions	<input type="checkbox"/> Yes <input type="checkbox"/> No
Oral cavity lesions	<input type="checkbox"/> Yes <input type="checkbox"/> No

Thank you for your cooperation
Researcher / Mona M. Hamam

Questionnaire

أنا الباحثة /منى حمام (طالبة ماجستير بالجامعة الإسلامية). أرجو المساعدة في تعبئة هذا الاستبيان من أجل عمل بحث حول دور هرمون الاوبستاتين عند مرضى السكري من النوع الثاني من الاناث في غزة.

بيانات شخصية	
رقم التليفون	
الاسم	
العمر	
المرحلة الدراسية	<input type="checkbox"/> جامعة او دبلوم <input type="checkbox"/> ثانوية عامة <input type="checkbox"/> المرحلة الاعدادية <input type="checkbox"/> المرحلة الابتدائية <input type="checkbox"/> أمي
هل يعاني أحد أفراد عائلتك من مرض السكري من النوع الثاني؟	<input type="checkbox"/> نعم <input type="checkbox"/> لا
BMI	الوزن: الطول:
هل تتبع حمية غذائية ؟	<input type="checkbox"/> نعم <input type="checkbox"/> لا
بيانات طبية (خاص بمرضى السكري)	
كم كان عمرك وقت تشخيص المرض؟	
في أي عام تم تشخيص السكري لأول مرة لديك؟	
ما هو نوع العلاج الذي تتناوله؟	
مضاعفات مرض السكري	
مشاكل في العين	<input type="checkbox"/> نعم <input type="checkbox"/> لا
أمراض القلب	<input type="checkbox"/> نعم <input type="checkbox"/> لا
مشاكل في الأعصاب	<input type="checkbox"/> نعم <input type="checkbox"/> لا
عدوى متكررة	<input type="checkbox"/> نعم <input type="checkbox"/> لا
مشاكل في الجلد	<input type="checkbox"/> نعم <input type="checkbox"/> لا
تقرحات في الفم	<input type="checkbox"/> نعم <input type="checkbox"/> لا

Bibliography

Abu Mustafa A. (2011): Leptin status and some biochemical parameters in type 2 diabetic males with diabetic nephropathy in Gaza Strip. Master Thesis, The Islamic University of Gaza.

Abu Snayma, F. (2012): Ghrelin, leptin and insulin in type 2 diabetic patients in Gaza Strip. Master Thesis, The Islamic University- Gaza.

Agnew, A.; Calderwood, D.; Chevallier, OP.; Greer, B.; Grieve, DJ. and Green, BD. (2011): Chronic treatment with a stable obestatin analogue significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats. *Peptides* 32: 755–762.

Al-Hakeim H.K. and Ali M.M. (2012): Low Ghrelin Level is Associated with Poor Control and Bad Prognosis Parameters in Obese Diabetic Patients. *Journal of Diabetology* 1(5): 1-10.

Altawil, H. (2009): Leptin Status and some Biochemical Parameters among type 2 Diabetic Females in the Gaza Governorate, Gaza Strip. Master Thesis, The Islamic University- Gaza.

American Diabetes Association (2004): Nephropathy in Diabetes Clinical Practice Recommendations. *Diabetes Care* 27(Suppl1): S79-83.

Annis, AM.; Caulder, MS. and Cook, ML. (2005): Family history, diabetes and other demographic and risk factors among participants of the national health and nutrition examination survey 1999–2002. *Preventing Chronic Disease* 2: 1-12.

Aydin, S.; Ozkan, Y.; Erman, F.; Gurates, B.; Kilic, N.; Colak, R.; Gundogan, T.; Catak, Z.; Bozkurt, M.; Akin, O.; Sen, Y. and Sahn, I. (2008): Presence of obestatin in breast milk: relationship among obestatin, ghrelin, and leptin in lactating women. *Nutrition* 24(7-8):689-93.

Backstrom, C. and Hursh-Cesar, G. (1981): Survey research, 2nd ed. london: Macmillan, pp.128-140.

Bánhidý, F.; Acs, N.; Puhó, EH.; et al. (2011): Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertension Research: Official Journal of the Japanese Society of Hypertension 34:257–63.

Bardin, C.W. (1994): Current therapy in endocrinology and metabolism. St.Louis: Mosby. 5th ed. pp: 406-411.

Barrett-Connor, E.; Grundy, SM. and Holdbrook, MJ. (1982): Plasma lipids and diabetes mellitus in an adult community. American Journal of Epidemiology 115: 657-663.

Bate, K. and Jerums, G. (2003): Preventing complications of diabetes. The Medical Journal of Australia 179(9): 498-503.

Bassil, AK.; Haˆglund, Y.; Brown, J.; Rudholm, T.; Hellstroˆm, PM.; Naˆslund, E.; Lee, K. and Sanger, GJ. (2007): Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. British Journal of Pharmacology 150(1): 58–64.

Botion, L. M. and Green, A. (1999): Long-term regulation of lipolysis and hormone sensitive lipase by insulin and glucose. Diabetes 48(9): 1691-1697.

Bresciani, E.; Rapetti, D.; Donà, F.; Bulgarelli, I.; Tamiazzo, L.; Locatelli, V. and Torsello, A. (2006): Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. Journal of Endocrinological Investigation 29(8): RC16–18.

Camiña, JP.; Campos, JF.; Caminos, JE.; Dieguez, C. and Casanueva, FF. (2007): Obestatin - mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms. Journal of Cellular Physiology 211(1): 1–9.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2003

Carlini, VP.; Schiöth, HB. and Debarioglio, SR. (2007): Obestatin improves memory performance and causes anxiolytic effects in rats. *Biochemical and Biophysical Research Communications* 352(4): 907–912.

Catalán, V.; Gómez-Ambrosi, J.; Rotellar, F.; Silva, C.; Gil, MJ. Rodríguez, A.; Cienfuegos, JA.; Salvador, J. and Frühbeck, G. (2007): The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. *Clinical Endocrinology* 66(4):598-601.

Cavallerano, j. (2009): Optometric clinical Practice Guideline, Care Of The Patient With Diabetes Mellitus, Reference Guide For Clinicians. American Optometric Association, U.S.A. P 15.

Centers for Disease Control and Prevention (2007): National Diabetes Fact Sheet: National Estimates And General Information On Diabetes And Prediabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services.

Centers for Disease Control and Prevention, (2008): National Diabetes Fact Sheet.

Centers for Disease Control and Prevention (2011): National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services.

Chanoine, JP.; Wong, AC. and Barrios V. (2006): Obestatin, acylated and total ghrelin concentrations in the perinatal rat pancreas. *Hormone Research* 66(2):81–88.

Chen, CY.; Asakawa, A.; Fujimiya, M.; Lee, SD. and Inui, A. (2009): Ghrelin gene products and the regulation of food intake and gut motility. *Pharmacological Reviews* 61(4):430-81.

Chen, Y.; Yun Huang, Y.; Li, X.; Xu, M.; Bi, Y.; Zhang, Y.; Gu, W. and Ning, G. (2009): Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension. *Endocrine* 36:262–267.

Chen, CY.; Doong, ML.; Li, CP.; Liaw, WJ.; Lee, HF.; Chang, FY.; Lin, HC. and Lee, SD. (2010): A novel simultaneous measurement method to assess the influence of intracerebroventricular obestatin on colonic motility and secretion in conscious rats. *Peptides* 31(6):1113-7.

Cnop, M. (2008): Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. *Biochemical Society Transactions* 36(Pt 3):348-52.

Cohen P., (2006): The 20th century struggle to decipher insulin signaling. *Nature Reviews, Molecular Cell Biology* 7: 867-873.

Debra Manzella, RN. (2006): Diabetic neuropathy is a long-term complication of both Type 1 and Type 2 diabetes, bout.com.

Debra Manzella, RN. (2008): Kidney disease in diabetes. <http://diabetes.about.com/od/preventingcomplications/p/kidneydisease>.

DeFronzo, R.A. and Simonson, D.C. (1992): Glucose toxicity in: *Advances in Endocrinology and Metabolism*. Vol. 3 Louis, M.O. Mosby, P. 1-53.

d’Emden, MC.; Shaw, JE.; Colman, PG.; Colagiuri, S.; Twigg, SM.; Jones, GRD.; Goodall, I.; Schneider, HG. and Cheung, NW. (2012): The role of HbA1c in the diagnosis of diabetes mellitus in Australia. *Medical Journal of Australia* 197 (4): 220-221.

Delhanty, PJ.; van der Eerden, BC.; van der Velde, M.; Gauna, C.; Pols, HA.; Jahr, H.; Chiba, H.; Van Der Lely, AJ. and Van Leeuwen, JP.(2006): Ghrelin

and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS R1a. *The Journal of Endocrinology* 188(1): 37–47.

Depoortere, I.; Thijs, T.; Moechars, D.; De Smet, B.; Ver Donck, L. and Peeters, T.L. (2008): Effect of peripheral obestatin on food intake and gastric emptying in ghrelin-knockout mice. *British journal of pharmacology* 153(7):1550-7.

De Smet, B.; Thijs, T.; Peeters, T.L. and Depoortere, I. (2007): Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents. *Neurogastroenterology and Motility*, 19(3):211–217.

Dun, S.L.; Brailoiu, G.C.; Brailoiu, E.; Yang, J.; Chang, J.K. and Dun, N.J. (2006): Distribution and biological activity of obestatin in the rat. *The Journal of Endocrinology* 191(2):481–489.

Dyck, P.; Feldman, E. and Vinik, A. (2002): *Diabetic Neuropathies The Nerve Damage of Diabetes*. The national diabetes information clearing house, National Institutes of Health Publication No. 02-3185.

El Meligi Amr, A.; El Kateb, Sara M. and El Khawaga, Azza M. (2003): Elevated Serum Leptin Levels in Type 2 Diabetic Patients With Diabetic Nephropathy. *Scientific Medical Journal (ESCME)*, 15.

Fujita, M.; Ueno, K. and Hata, A. (2009): Effect of obesity on incidence of type 2 diabetes declines with age among Japanese women. *Experimental Biology and Medicine* 234:750-757.

Furth, A.J. (1997): Glycated proteins in diabetes. *British Journal of Biomedical Sciences* 54(3):192-200

Goldstein, D.E.; Little, R.R.; Lorenz, R.A.; Malone, J.I.; Nathan, D. and Peterson, C.M. (2004): Tests of glycemia in diabetes. *Diabetes Care* 27:1761–63.

Gourcerol, G.; St-Pierre, DH. and Tache, Y. (2007): Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? *Regulatory Peptides* 141(1-3):1–7.

Granata, R.; Settanni, F.; Gallo, D.; Trovato, L.; Biancone, L.; Cantaluppi, V.; Nano, R.; Annunziata, M.; Campiglia, P.; Arnoletti, E.; Ghè, C.; Volante, M.; Papotti, M.; Muccioli, G. and Ghigo, E. (2008): Obestatin promotes survival of pancreatic-cells and human islets and induces expression of genes involved in the regulation of cell mass and function. *Diabetes* 57(4):967-979.

Green, BD.; Irwin, N. and Flatt, PR. (2007): Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. *Peptides* 28:981–987.

Grönberg, M.; Tsolakis, AV.; Magnusson, L.; Janson, ET. And Saras, J. (2008): Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands. *Journal of Histochemistry & Cytochemistry* 56(9):793-801.

Harris, M.; Fishbein, H.; Palumbo, P. and Kuller L. (1995): *Diabetes in America*, 2nd ed. The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

Hassouna, R.; Zizzari, P. and Tolle, V. (2010): The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. *Journal of Neuroendocrinology* 22(7):793-804.

Holst, JJ. (2007): The physiology of glucagon-like peptide 1. *Physiological reviews* 87: 1409–1439.

Jack, (2012): Study of correlations between plasma obestatin and relevant factors in the different glucose tolerances. *Medical Research, Endocrine*.

Jackson, VR.; Nothacker, HP. and Civelli, O. (2006): GPR39 receptor expression in the mouse brain. *Neuroreport* 17(8):813–816.

Jaworski, K.; Sarkadi-Nagy, E. and Duncan, RE. (2007): Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. American Journal of Physiology, Gastrointestinal and Liver Physiology 293: G1-G4.

Jeffery, PL.; Duncan,RP.; Yeh, AH.; Jaskolski. RA.; Hammond,DS.; Herington, AC. and Chopin, LK. (2005): Expression of the ghrelin axis in the mouse: an exon 4-deleted mouse proghrelin variant encodes a novel C terminal peptide. Endocrinology 146(1):432–440.

Kapica, M.; Zabielska, M.; Puzio, I.; Jankowska, A.; Kato, I.; Kuwahara, A. and Zabielski, R. (2007): Obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats—preliminary results. Journal of Physiology and Pharmacology 58(3):123–130.

Katsiki, N.; Mikhailidis, DP.; Gotzamani-Psarrakou, A.; Yovos, JG. and Karamitsos, D. (2011): Effect of Various Treatments on Leptin, Adiponectin, Ghrelin and Neuropeptide Y in Patients With Type 2 Diabetes Mellitus. Expert Opinion on Therapeutic Targets 15: 401-20.

Lagaud, GJ.; Young, A.; Acena, A.; Morton, MF.; Barrett, TD. and Shankley, NP. (2007): Obestatin reduces food intake and suppresses body weight gain in rodents. Biochemical and Biophysical Research Communication, 357(1):264–269.

Lago, R.; Gomez, R.; Dieguez, C.; Gomez-Reino, JJ.; Lago, F. and Gualillo, O. (2007): Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. Annals of the Rheumatic Disease, 66(10):1399–1400.

Lauwers, E.; Landuyt, B.; Arckens, L.; Schoofs, L. and Luyten, W. (2006): Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochemical and Biophysical Research Communications 351(1):21-5.

Lippl, F.; Erdmann, J.; Lichter, N.; Tholl, S.; Wagenpfeil, S.; Adam, O. and Schusdziarra, V. (2008): Relation of Plasma Obestatin Levels to BMI, Gender, Age and Insulin. *Hormone and Metabolic Research* 40(11): 806-812.

Maeda, Y. and Shiigai, T. (2007): Diet Therapy in Diabetic Nephropathy". *Nutrition and Kidney Disease: A New Era* 155: 50–58.

Marshall, S. and Flyvbjerg, A. (2006): Prevention and Early Detection of Vascular Complications of Diabetes. *British Medical journal* 333: 475-480.

Mészárosóvá, M.; Sirotkin, AV.; Grossmann, R.; Darlak, K. and Valenzuela, F. (2008):The effect of obestatin on porcine ovarian granulosa cells. *Animal Reproduction Science*, 108(1-2):196-207.

Michael, R.; Kulkarni, C.; Postic, S.; Previs, G.; Shulman, M.; Magnuson, C. and Kahn, CR. (2000): Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Molecular Cell* 6(1): 87-97.

Miegunu, P.; St Pierre, D.; Broglia, F. and Cianflone, K. (2011): Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. *Journal of Cellular Biochemistry* 112(2):704-14.

Ministry of Health, (2002): Health status in Palestine, Annual Report 2001, State of Palestine, Ministry of Health ; Health Management Information Center (HMIS).

Ministry of Health, (2005): Health status in Palestine, Annual Report 2004, State of Palestine, Ministry of Health ; Health Management Information Center (HMIS).

Ministry of Health, (2009): Health status in Palestine, Annual Report 2008, State of Palestine, Ministry of Health ; Health Management Information Center (HMIS).

Ministry of Health, (2010): Health status in Palestine, Annual Report 2009, State of Palestine, Ministry of Health ; Health Management Information Center (HMIS).

Mondal, MS.; Toshinai, K.; Ueno, H.; Koshinaka, K. and Nakazato, M. (2008): Characterization of obestatin in rat and human stomach and plasma, and its lack of acute effect on feeding behavior in rodents. *Journal of Endocrinology*, 198(2): 339–346.

Nagaraj, S.; Peddha, MS. and Manjappara, UV. (2008): Fragments of obestatin as modulators of feed intake, circulating lipids, and stored fat. *Biochemical and Biophysical Research Communications* 366:731–7.

Nagaraj, S.; Peddha, MS. and Manjappara, UV. (2009): Fragment analogs as better mimics of obestatin. *Regulatory Peptides* 158:143–8.

Nogueiras, R.; Pfluger, P.; Tovar, S.; Arnold, M.; Mitchell, S.; Morris, A.; Perez-Tilve, D.; Vázquez, MJ.; Wiedmer, P.; Castañeda, TR.; DiMarchi, R.; Tschöp, M.; Schurmann, A.; Joost, HG.; Williams, LM.; Langhans, W. and Diéguez, C. (2007): Effects of obestatin on energy balance and growth hormone secretion in rodents. *Endocrinology* 148(1):21–26.

Olefsky, JM. (2001): Prospects for Research in diabetes mellitus. *The Journal of American Medical Association* 285(5): 628-632.

Ozbay, Y.; Aydin, S.; Dagli, AF.; Akbulut, M.; Dagli, N.; Kilic, N.; Rahman, A.; Sahin, I.; Polat, V.; Ozercan, HI.; Arslan, N. and Sensoy, D. (2008): Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. *Biochemistry and Molecular Biology reports* 41(1):55-61.

Palestinian clinical laboratory tests guide, PCLTG, 2005

Pijl, M.; Henneman, L. and Claassen, L. (2009): Family history of diabetes: exploring perceptions of people at risk in the Netherlands. *Preventing Chronic Disease*; 6: A54.pp. 128–40.

Qader, SS.; Håkanson, R.; Rehfeld, JF.; Lundquist, I. and Salehi, A. (2008): Proghrelin-derived peptides influence the secretion of insulin, glucagon, pancreatic polypeptide and somatostatin: a study on isolated islets from mouse and rat pancreas. *Regulatory Peptides*146:230–237.

Qi, X.; Li, L.; Yang, G.; Liu, J.; Li, K.; Tang, Y.; Liou, H. and Boden, G. (2007): Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. *Clinical Endocrinology* 66(4):593-7.

Samson, WK.; White, MM.; Price, C. and Ferguson, AV. (2007): Obestatin acts in brain to inhibit thirst. *American Journal of Physiology - Regulatory, Integrative and Comparative Physiology* 292:R637–643.

Savage, DB.; Petersen, KF. and Shulman, GI. (2005): Mechanisms of Insulin Resistance in Humans and Possible Links with Inflammation. *Hypertension* 45:828–833.

Savage, P. (1996): Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. *Annals of Internal Medicine*, Vol.124, No.1:123-126.

Scheen, AJ. (2003): Pathophysiology of type 2 diabetes. *Acta Clinica Belgica* 58(6):335-41.

Seoane, LM.; Al-Massadi, O.; Pazos, Y.; Pagotto, U. and Casanueva, FF. (2006):Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. *Journal of Endocrinology Investigation*29(8):RC13–15.

Sharma, A.; Hirulkar, N.B.; Wadel, P. and Das, P. (2011): Influence of Hyperglycemia on Renal Function Parameters in Patients with Diabetes

Mellitus. International Journal of Pharmaceutical & Biological Archives 2(2):734-739

Soares, J. and Leite-Moreira, AF. (2008): Ghrelin, des-acyl ghrelin and obestatin: Three pieces of the same puzzle. Peptides, 29:1255–1270.

St-Pierre, DH.; Settanni, F.; Olivetti, I.; Gramaglia, E.; Tomellini, M.; Granata, R.; Prodam, F.; Benso, A.; Ghigo, E. and Broglio, F. (2010): Circulating obestatin levels in normal and Type 2 diabetic subjects. Journal of Endocrinological investigation 33(4):211-4.

Susztak, K.; Sharma, K.; Schiffer, M.; McCue, P.; Ciccone, E. and Böttinger, EP. (2003): Genomic Strategies for Diabetic Nephropathy. Journal of American Society of Nephrology 14(8 Suppl 3):S271-8. Review.

Szentirmai, E. and Krueger, JM. (2006b): Obestatin alters sleep in rats. Neuroscience Letters 404(1-2):222–226.

Szentirmai, E.; Kapa's, L.; Sun, Y.; Smith, RG. and Krueger, JM.(2009):The preproghrelin gene is required for the normal integration of thermoregulation and sleep in mice. Proceedings of the national Academy of Science of the united states of America 106(33):14069–14074.

The National Eye Institute, (2006): Diabetic Retinopathy. National Institutes of Health Publication No. 04-3252.

Varghese, A.; Deepa, R.; Rema, M. and Mohan, V. (2001): Prevalence of Microalbuminuria in Type 2 Diabetes Mellitus at a Diabetes Centre in Southern India. Postgraduate Medical Journal 77:399–402.

Vergote, V.; Dorpe, SV.; Peremans, K.; Burvenich, C. and Spiegeleer, BD. (2008): In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides, 29 (10):1740-1748.

Wallum, BJ.; Kahn, SE.; McCulloch, DK. and Porte, D. (1992): Insulin secretion in the normal and diabetic human. In International Textbook of

Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. Chichester, U.K., John Wiley and Sons, p.285 –301

Waltkins, p. (2003): ABC of diabetes, 5th ed. ISBN 0-7279-16939. P:10-20.

Wild, S.; Roglic, G.; Green, A.; Sicree, R. and King, H. (2004): Global Prevalence of Diabetes: Estimates for the Year 2000 to 2030. *Diabetic Care* 27(5): 1047-1053.

Wilkin, TJ. (2006): The accelerator hypothesis: a unifying explanation for type-1 and type-2 diabetes. *Nestle Nutrition Workshop Series. Clinical & Performance Programme*.11:139-50; discussion 150-3.

Wroblewska-Seniuk, K.; Wender-Ozegowska, E. and Szczapa, J. (2009): Long-term effects of diabetes during pregnancy on the offspring. *Pediatr Diabetes* 10:432–40.

World Health Organization, (2000): Obesity: Preventing and managing the global epidemic. Report of WHO, consultation on obesity. Technical report series; No 894.

World Health Organization, WHO. (2003): Non communicable disease prevention and health promotion: Facts related to chronic disease; Factsheet – diabetes, Geneva, Switzerland.

Yamamoto, D.; Ikeshita, N.; Daito, R.; Herningtyas, EH.; Toda, K.; Takahashi, K.; Iida, K.; Takahashi, Y.; Kaji, H.; Chihara, K. and Okimura, Y. (2007): Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and ACTH in rats. *Regulatory Peptides* 138:141–144.

Yamamoto, H.; Kishi, T.; Lee, CE.; Choi, BJ.; Fang, H.; Hollenberg, AN.; Drucker, DJ. And Elmquist, JK. (2003): Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like

peptide-1 with central autonomic control sites. The journal of neuroscience 23(7):2939-46.

Yassin, M.; Altibi, H. and El Shanti, A. (2011): clinical and biochemical features of type 2 diabetic patients in Gaza Governorate, Gaza Strip. West African Journal of Medicine.

Zhang, JV.; Ren, P.; Avsian-Kretchmer, O.; Luo, C.; Rauch, R.; Klein, C. and Hsueh, AJ. (2005): Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science, 310:996–999.

Zhang, JV.; Jahr, H.; Luo, C.; Klein, C.; Kolen, KV.; Donck, LV.; De, A.; Baart, E.; Li, J.; Moechars, D. and Hsueh, AJ. (2008): Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein coupled receptor, GPR39. Molecular Endocrinology 22(6):1464–1475.

Zizzari, P.; Longchamps, R.; Epelbaum, J. and Bluet-Pajot, M. (2007): Obestatin partially affects ghrelin stimulation of food intake and GH secretion in rodents. Endocrinology 148(4):1648–1653.